Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/67—General methods for enhancing the expression
  • C12N15/68—Stabilisation of the vector
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Definitions

• the present invention relates to plasmid DNA liquid formulations that are stable and where the plasmid stays un-degraded at +4 0 C to room temperature for long periods of time. Such formulations are thus useful for the storage of plasmid DNA used in research or in plasmid-based therapy, such as DNA vaccines and gene therapy.
• Plasmid DNA is a covalently closed circular (ccc) or supercoiled form of bacterial DNA into which a DNA sequence of interest can be inserted.
• DNA sequences of interest that may be introduced in mammalian cells include exogenous genes, functional genes, or mutant genes, antisense sequences, RNAi or dsRNAi sequences, ribozymes, and those for uses in, for example, DNA vaccines against viral infection, or in the treatment of cardiovascular diseases, angiogenesis-related diseases, or cancer.
• the plasmid DNA Once delivered to the human cell, the plasmid DNA begins replicating and producing copies of the inserted DNA sequence.
• API active pharmaceutical ingredients
• Oxidation agents e.g., hydrogen peroxide, superoxide and hydroxyl radicals that are generated through Fenton-type reactions are responsible for DNA oxidative degradations.
• Plasmid DNA is usually formulated in phosphate or Tris-buffered aqueous solutions, wherein the phosphate or Tris buffer is present at a concentration of around 10 mM. Such compositions are however generally subject to degradation processes that occur during storage in aqueous solution. These plasmid DNA solutions have very poor stability both at around +4°C and +25 0 C.
• plasmids DNA are commonly lyophilized for storage at temperatures that extend to room-temperature, but then requiring additional manipulation steps of reformulations and further risks of contaminations and/or degradations.
• any strand breakage that occurs in plasmid DNA affects the quality and performance, it is critical to address the damages that occur over time during storage and manipulations of plasmid DNA, and provide with a storage composition ensuring long term storage stability of the plasmid DNA and safe manipulations at extended temperatures ranging from +4 0 C to room temperature.
• novel liquid compositions for plasmid DNA that are stable and resistant to a broad range of temperatures, e ⁇ g., up to room temperature for long period of time, thus facilitating storages, transportations, manipulations, and distributions of the DNA-based drug, DNA vaccines or gene therapy before safe administrations to the subjects.
• liquid formulations are useful for highly purified plasmid DNA which may used for research and plasmid-based therapy, e.g., in gene therapy and DNA vaccine.
• a first object of the present invention is a composition for preserving plasmid DNA in a liquid formulation for long periods of time at temperatures up to +25 0 C.
• the present invention thus relates to a stable plasmid DNA liquid storage composition
• a stable plasmid DNA liquid storage composition comprising a plasmid DNA and a buffer in a concentration up to 5mM, up to 4mM, or up to 3mM, or again up to 2mM that is sufficient to maintain the pH the plasmid DNA composition between 6 and 9, thereby allowing to preserve the plasmid DNA with a supercoiled content of at least 80%, and a content of plasmids subject depurination and nicking of less than 20%.
• the present invention also relates to a stable plasmid DNA liquid storage composition
• a stable plasmid DNA liquid storage composition comprising a plasmid DNA and a buffer solution in a concentration of up to 2mM sufficient to maintain the pH of said formulation or composition between 6.2 and 8.5, and/or approximately +/- 0.3 from one or both of these values, thereby preserving the plasmid DNA with depurination and nicking rates of less than 5% per year when stored at around +4 0 C and less than 5% per month when stored at around +25 0 C.
• the present invention also relates to a stable plasmid DNA liquid storage composition
• a stable plasmid DNA liquid storage composition comprising a plasmid DNA and a buffer solution in a concentration of up to 2mM sufficient to maintain the pH of said formulation or composition between 6.7 and 8.0, and/or approximately +/- 0.3 from one or both of these values, thereby preserving the plasmid DNA with depurination and nicking rates of less than 2% per year when stored at around +4 0 C and less than 2% per month when stored at around +25°C.
• the present invention further relates to a stable plasmid DNA liquid storage composition
• a stable plasmid DNA liquid storage composition comprising a plasmid DNA and a buffer solution in a concentration of up to 2mM sufficient to maintain the pH of said formulation or composition between 7.0 and 7.5, approximately +/- 0.3, thereby allowing to preserve the plasmid DNA with depurination and nicking rates of less than 1% per year when stored at around +4 0 C and less than 1% per month when stored at around +25 0 C.
• Another object of the present invention is a method of preserving plasmid DNA in a stable form in a storage liquid composition, comprising (i) preparing a purified sample of plasmid DNA; (ii) combining said purified sample of plasmid DNA and a buffer solution in a concentration of up to 2mM sufficient to maintain the pH of the resulting composition between 6 and 9; and (iii) storing the plasmid DNA.
• the method according to the present invention allows one to preserve high quality plasmid DNA with at least 80% supercoiled plasmid DNA.
• the present invention relates to a method of preserving plasmid DNA in a stable form in a storage liquid composition at temperatures around +4 0 C to +25 0 C with depurination and nicking rates of less than 5% per month to less than 5% per year, comprising (i) preparing a purified sample of plasmid DNA; (ii) combining said purified sample of plasmid DNA and a buffer solution in a concentration of up to 2mM sufficient to maintain the pH of the resulting composition between 6.2 and 8.5 and/or approximately +/- 0.3 from one or both of these values; and (iii) storing the plasmid DNA at the selected temperature.
• the present invention also relates to a method of preserving plasmid DNA in a stable form in a storage liquid composition at temperatures around +4 0 C to +25 0 C with depurination and nicking rates of less than 2% per month to less than 2% per year, comprising (i) preparing a purified sample of plasmid DNA; (ii) combining said purified sample of plasmid DNA and a buffer solution in a concentration of up to 2mM sufficient to maintain the pH of the resulting composition between 6.7 and 8 or approximately +/- 0.3 from one or both of these values; and (iii) storing the plasmid DNA at the selected temperature.
• the present invention further relates to a method of preserving plasmid DNA in a stable form in a liquid composition at temperatures around +4 0 C to +25 0 C with depurination and nicking rates of less than 1% per month to less than 1% per year, comprising (i) preparing a purified sample of plasmid DNA; (ii) combining said purified sample of plasmid DNA and a buffer solution in a concentration of up to 2mM sufficient to maintain the pH of the resulting composition between 7.0 and 7.5 and/or approximately +/- 0.3 from one or both of these values; and (iii) storing the plasmid DNA at the selected temperature.
• the composition of plasmid DNA comprises a buffer solution in a concentration of less than 5 mM, or less than 4mM, or less than 3mM.
• the stable plasmid DNA storage composition comprises a buffer solution in a traces level or in a very diluted concentration up to 2mM, and more preferably between ImM and 2mM.
• the buffer solution is present in a concentration less than ImM, between 250 ⁇ M and ImM, or between 400 ⁇ M and ImM, so as to maintain the pH of said formulation or composition between 6 and 9, or between 6.2 and 8.5, preferably between 6.7 and 8, and most preferably between 7 and 7.5, and/or approximately +/- 0.3 from any one or more of these values.
• the stable composition according to the present invention is particularly useful for storing highly purified plasmid DNA, that have very low levels of contaminating chromosomal DNA, RNA, protein, and endotoxins.
• Such highly purified plasmids DNA have less than about 0.01% host cell RNA contaminant, and/or less than about 0.01% host cell protein contaminant, and/or less than about 0.01% host cell genomic DNA contaminant.
• Preferred highly purified plasmids DNA have less than about 0.001% host cell RNA contaminant, and/or less than about 0.001% host cell protein contaminant, and/or less than about 0.001% host cell genomic DNA contaminant.
• Most preferred highly purified plasmids DNA have less than about 0.0001% host cell RNA contaminant, and/or less than about 0.0001% host cell protein contaminant, and/or less than about 0.0001% host cell genomic DNA contaminant.
• Still another object of the present invention is a method of preparing a stable plasmid DNA liquid composition for storage at a temperature of up to about 25°C, comprising (1 ) a step of lysing cells comprising flowing the cells through (a) a turbulent flow to rapidly mix a cell suspension with a solution that lyses cells; and (b) a laminar flow to permit incubating a mixture formed in (a) without substantial agitation, wherein the mixture formed in (a) flows from the turbulent flow into the laminar flow, and optionally further comprising (c) adding a second solution that neutralizes the lysing solution, the mixture incubated in (b) the laminar flow into the second solution, so as to release plasmids DNA from the cells; (2) one step of chromatography for purifying the plasmid DNA so released; (3) combining said purified plasmid DNA and a buffer solution in a concentration of up to 2mM sufficient to maintain the pH of the resulting composition between 6 and 9, and (4) storing
• the present invention also relates to a method of preparing a stable plasmid DNA liquid formulation for storage at a temperature of up to about 25°C, comprising (1) a step of lysing cells comprising flowing the cells through (a) a means for turbulent flow to rapidly mix a cell suspension with a solution that lyses cells; and (b) a laminar flow to permit incubating a mixture formed in (a) without substantial agitation, wherein the mixture formed in (a) flows from the turbulent flow into the laminar flow, and optionally further comprising (c) a means for adding a second solution that neutralizes the lysing solution, the mixture incubated in (b) flowing from the means for laminar flow into the means for adding a second solution, so as to release plasmids DNA from the cells; (2) performing a step of chromatography for purifying the plasmid DNA so released; (3) performing a step of diafiltration and/or buffer exchange; (4) combining said purified plasmid DNA with a buffer
• the buffer solution is added to the composition of plasmid DNA in a concentration of less than 5 mM, or less than 4mM, or less than 3mM.
• the method comprises the addition of traces levels of the buffer solution or the addition of a buffer solution in a very diluted concentration up to 2mM, and more preferably between ImM and 2mM.
• the buffer solution is present in a concentration less than ImM, between 250 ⁇ M and ImM, or between 40OuM and ImM, so as to maintain the pH of said formulation or composition between 6 and 9, or between 6.2 and 8.5, preferably between 6.7 and 8, and most preferably between 7 and 7.5, and/or approximately +/- 0.3 from any one or more of these values.
• a further object of the present invention is the vials containing stable plasmid DNA liquid formulation as an active pharmaceutical ingredient for use in research or plasmid-based therapy, such as gene therapy or DNA vaccine.
• Still a further object of the present invention is the vial containing a purified plasmid DNA is a plasmid designated NVlFGF which is a pCOR plasmid carrying an expression cassette encoding for the FGF-I gene, that is useful for treatment of peripheral limb ischemia, including peripheral arterial disease (PAOD or PAD) and critical limb ischemia (CLI).
• PAOD peripheral arterial disease
• CLI critical limb ischemia
• Figure 1 is a schematic of the apparatus that may be used for continuous mode cell lysis of the invention.
• Figure 2 is a schematic of the mixer Ml in the continuous cell lysis apparatus.
• Figure 3 is a table comparing purification yields in terms of gDNA, RNA, proteins, endotoxin contaminant using a single step of anion exchange chromatography (AEC), or a two-step method with a step of anion exchange chromatography in combination with triple helix affinity chromatography (THAC), and a three-step method comprising a step of anion exchange chromatography, a step triple helix affinity chromatography and a step of hydrophobic interaction chromatography (HIC) in combination ND means not detected : low sensitivity analytical methods.
• AEC anion exchange chromatography
• THAC triple helix affinity chromatography
• HIC hydrophobic interaction chromatography
• Figure 4 is a table comparing various methods of separating and purifying plasmid DNA, such anion-exchange chromatography (AEC), hydroxyapatite chromatography (HAC), hydrophobic interaction chromatography (HIC), reversed-phase chromatography (RPC), size exclusion chromatography (SEC), triple helix affinity chromatography (THAC) alone or in combination, and the method according to the present invention.
• AEC anion-exchange chromatography
• HAC hydroxyapatite chromatography
• HIC hydrophobic interaction chromatography
• RPC reversed-phase chromatography
• SEC size exclusion chromatography
• THAC triple helix affinity chromatography
• Figures 5A and 5B are graphs showing depurination and nicking rates (formation of open circular plasmid form) of the plasmid DNA stored at +25°C and +5°C for up to 90 days.
• Figures 6A and 6B are graphs showing depurination and nicking rates (formation of open circular plasmid form) of the plasmid DNA stored at +25 0 C and +5 0 C for up to 150 days.
• Plasmid DNA formulation or composition means a composition comprising an efficient amount of plasmid DNA or a formulation of a plasmid DNA present in an efficient amount for use in research or plasmid-based therapy, such as gene therapy or DNA vaccine.
• Stable storage plasmid DNA formulation means a formulation that may be used for storage of plasmid DNA in a stable form for long periods of time before use as such for research or plasmid-based therapy. Storage time may be as long as several months, 1 year, 5 years, 10 years, 15 years, or up to 20 years at temperature range from +5°C to +25°C (RT: room temperature).
• a stable plasmid DNA formulation or composition means a plasmid DNA formulation that has a proportion of supercoiled double-strand DNA of at least 80%, the reminder being in the form of open circular or/and linear plasmids.
• a stable plasmid DNA formulation hereinafter means a composition comprising plasmid DNA that has depurination and nicking rates (formation of open circular plasmid form) of less than 5% per month when stored at +25°C and less than 5% per year when stored at +5°C.
• a stable plasmid DNA formulation hereinafter means a composition comprising plasmid DNA that has depurination and nicking rates (formation of open circular plasmid form) of less than 2% per month when stored at +25°C and less than 2% per year when stored at +5°C.
• plasmid DNA More preferably is a stable plasmid DNA formulation hereinafter means a composition comprising plasmid DNA that has depurination and nicking raies (formation of open circular plasmid form) of less than 1% per month when stored at +25°C and less than 1% per year when stored at +5°C.
• Acidic means relating to or containing an acid; having a pH of less than 7.
• Alkaline means relating to or containing an alkali or base; having a pH greater than 7. Continuous means not interrupted, having no interruption.
• Genomic DNA (shortened as gDNA) means a DNA that is derived from or existing in a chromosome.
• Laminar flow means the type of flow in a stream of solution water in which each particle moves in a direction parallel to every particle.
• Lysate means the material produced by the process of cell lysis.
• the term lysing refers to the action of rupturing the cell wall and/or cell membrane of a cell which is in a buffered solution (£e., cell suspension) through chemical treatment using a solution containing a lysing agent. Lysing agents include for example, alkali, detergents, organic solvents, and enzymes.
• the lysis of cells is done to release intact plasmids from host cells. Neutralizes to make (a solution) neutral or to cause (an acid or base/alkali) to undergo neutralization. By this term we mean that something which neutralizes a solution brings the pH of the solution to a pH between 5 and 7, and preferably around 7 or more preferably closer to 7 than previously.
• Newtonian fluid is a fluid in which shear stress is proportional to the velocity gradient and perpendicular to the plane of shear.
• the constant of proportionality is known as the viscosity.
• Examples of Newtonian fluids include liquids and gasses.
• Non-Newtonian fluid is a fluid in which shear stress is not proportional solely to the velocity gradient and perpendicular to the plane of shear. Non-Newtonian fluids may not have a well defined viscosity. Non-Newtonian fluids include plastic solids, power-law fluids, viscoelastic fluids (having both viscous and elastic properties), and time-dependent viscosity fluids.
• Plasmid DNA means a small cellular inclusion consisting of a ring of DNA that is not a chromosome, which may have the capability of having a non-endogenous DNA fragment inserted into it.
• plasmid DNA can also be any form of plasmid DNA, such as cut, processed, or other manipulated form of a non-chromosomal DNA, including, for example, any of, or any combination of, nicked circle plasmid DNA, relaxed circle plasmid DNA, supercoiled plasmid DNA, cut plasmid DNA, linearized or linear plasmid DNA, and single-stranded plasmid DNA.
• Plasmids Procedures for the construction of plasmids include those described in Maniatis et al., Molecular Cloning, A Laboratory Manual, 2d, Cold Spring Harbor Laboratory Press (1989).
• a protocol for a mini-prep of plasmid DNA well-known in the art (Birnboim and DoIy, Nucleic Acids Research 7:1513 (1979)), can be used to initially isolate plasmid DNA for later processing through some aspects of the invention and can be contrasted with the highly purified samples produced from the methods of the invention.
• the form of the plasmid DNA is, or at least is after preparation by the purification method of the invention, substantially closed circular form plasmid DNA, or about 80%, 85%, 90%, 95%, or more than about 99% closed circular form plasmid DNA.
• a supercoiled covalently closed form of plasmid DNA ccc
• the pharmaceutical grade plasmid DNA may be isolated from or separated from one or more forms of plasmid and substantially comprise one or more desired forms.
• the term flowing refers to the passing of a liquid at a particular flow rate (eg., liters per minute) through the mixer, usually by the action of a pump. It should be noted that the flow rate through the mixer is believed to affect the efficiency of lysis, precipitation and mixing.
• DNA DNA that is not supercoiled.
• Supercoiled DNA is a term well understood in the art in describing a particular, isolated form of plasmid DNA. Other forms of plasmid DNA are also known in the art.
• a "contaminating impurity” is any substance from which it is desired to separate, or isolate, DNA. Contaminating impurities include, but are not limited to, host cell proteins, endotoxin, host cell DNA, such as chromosomal DNA or genomic DNA, and/or host cell RNA. It is understood that what is or can be considered a contaminating impurity can depend on the context in which the methods of the invention are practiced.
• a "contaminating impurity” may or may not be host cell derived, re., it may or may not be a host cell impurity.
• “Isolating” or “purifying” a first component means enrichment of the first component from other components with which the first component is initially found. Extents of desired and/or obtainable purification are provided herein.
• essentially free and highly purified are defined as about 95% and preferably greater than 98.99% pure or free of contaminants, or possessing less than 5%, and preferably less than 1 -2% contaminants.
• Pharmaceutical grade DNA is defined herein as a DNA preparation that contains no more than about 5%, and preferably no more than about 1-2% of cellular components, such as cell membranes.
• the plasmid DNA produced and isolated by the method of the invention contains very low levels, Le ⁇ part per millions (ppm) of contaminating chromosomal DNA, RNA, protein, and endotoxins, and contains mostly closed circular form plasmid DNA.
• the plasmid DNA produced according to the invention is of sufficient purity for use in research and plasmid-based therapy, and optionally for human clinical trial material and human gene therapy experiments and clinical trials.
• a "pharmaceutical grade plasmid DNA composition” of the invention is one that is produced by a method of the invention and/or is a composition having at least one of the purity levels defined below as a "pharmaceutical grade plasmid DNA.”
• a “pharmaceutical grade plasmid DNA composition” of the invention is of a purity level defined by at least two of those identified below as a "pharmaceutical grade plasmid DNA” for example, less than about 0.01% chromosomal or genomic DNA and less than about 0.01% protein contaminant, or for example less than about 0.01% chromosomal or genomic DNA and less than about 0.1 EU/mg endotoxins.
• Pharmaceutical grade plasmid DNA preferably contains less than about 0.001% chromosomal or genomic DNA and less than about 0.001% protein contaminant, or for example less than about 0.001% chromosomal or genomic DNA and less than about 0.1 EU/mg endotoxins. More preferably, it contains less than about 0.0001% chromosomal or genomic DNA and less than about 0.0001% protein contaminant, or for example less than about 0.0001% chromosomal or genomic DNA and less than about 0.1 EU/mg endotoxins.
• Most preferred pharmaceutical grade DNA plasmid contains less than about 0.00008% chromosomal or genomic DNA and less than about 0.00005% protein contaminant, or for example less than about 0.00008% chromosomal or genomic DNA and less than about 0.1 EU/mg endotoxins. Other combinations of purity levels are included under the definition.
• the pharmaceutical grade plasmid DNA composition can further comprise or contain added components desired for any particular use, including use in combination treatments, compositions, and therapies.
• the levels of chromosomal or genomic DNA, RNA, endotoxins or protein refers to contaminants from the cell-based production of plasmid or other contaminant(s) from the purification process.
• “Pharmaceutical grade plasmid DNA” is defined herein as a DNA preparation that contains on the level of one part per million or ppm ( ⁇ 0.0001%, i.e. ⁇ 0.0001 mg per 100 mg of plasmid DNA) or less of genomic DNA, RNA, and/or protein contaminants.
• pharmaceutical grade plasmid DNA herein can mean a DNA preparation that contains less than about 0.01%, or less than 0.001%, and preferably less than 0.0001%, or preferably less than 0.00008% ( ⁇ 0.00008%, i.e. ⁇ 0.00008 mg per 100 mg of plasmid DNA) of chromosomal DNA or genomic DNA.
• “Pharmaceutical grade plasmid DNA” can also mean a DNA preparation that contains less than about 0.01%, or less than 0.001%, and preferably less than 0.0001%, or preferably less than 0.00002% ( ⁇ 0.00002%, i.e. ⁇ 0.00002 mg per 100 mg of plasmid DNA) of RNA contaminants.
• “Pharmaceutical grade plasmid DNA” can also mean a DNA preparation that contains less than about 0.0001%, and most preferably less than 0.00005% ( ⁇ 0.00005%, i.e. ⁇ 0.00005 mg per 100 mg of plasmid DNA) of protein contaminants.
• “Pharmaceutical grade plasmid DNA” can also mean a DNA preparation that contains less than 0.1 EU/mg endotoxins.
• the Pharmaceutical grade plasmid DNA means herein a DNA preparation that is preferably, predominantly circular in form, and more precisely DNA that contains more than 80%, 85%, 90%, 95%, or more than 99% of closed circular form plasmid DNA.
• T tube refers to a T-shaped configuration of tubing, wherein a T-shape is formed by a single piece of tubing created in that configuration or more than one piece of tubing combined to create that configuration.
• the T tube has three arms and a center area where the arms join.
• a T tube may be used to mix ingredients as two fluids can flow each into one of the arms of the T, join at the center area, and out the third arm. Mixing occurs as the fluids merge.
• Turbulent flow means irregular random motion of fluid particles in directions transverse to the direction of the main flow, in which the velocity at a given point varies erratically in magnitude and direction.
• Viscoelastic refers to fluids having both viscous and elastic properties.
• the present invention relates to plasmid DNA liquid formulations that are stable and where the plasmid DNA stays un-degraded at room temperature for a long period of time.
• plasmid DNA formulations or compositions are thus useful for the storage of plasmid DNA in research, plasmid-based therapy, such as gene therapy or DNA vaccine.
• the stable plasmid DNA liquid storage composition comprising a plasmid DNA and a buffer solution in a concentration up to 5mM, or up to 4mM, or up to 3mM, or up to 2mM that are sufficient to maintain the pH of said composition between 6 and 9, and the composition comprises predominant supercoiled form of plasmid DNA at temperatures around 4 0 C to 25 0 C, for several months, 1 year, 2 years, 3 years, 4, years, 5 years, and up to 10 years.
• a composition of plasmid DNA having predominantly supercoiled form of plasmid comprises at least 80% of supercoiled or closed circular plasmid DNA, or around 85%, and preferably around
• composition of stable plasmid DNA contains around 99% of supercoiled or closed circular form plasmid DNA.
• a stable composition for plasmid DNA storage yields depurination and nicking rates of less than 5% per month.
• the stable plasmid DNA liquid storage formulation according to the present invention thus comprises a plasmid DNA and a very diluted buffer solution a buffer solution in a concentration up to
• the stable plasmid DNA liquid composition comprises a buffer solution in a concentration up to 2mM so as to maintain the pH of said formulation or composition between 6.2 and 8.5, and/or approximately +/- 0.3 from one or both of these values, thereby allowing storage of the plasmid DNA with depurination and nicking rates of less than 5% per year when stored at around +4 0 C and less than 5% per month when stored at around +25 0 C.
• the stable plasmid DNA liquid composition comprises a buffer solution in a concentration up to 2mM so as to maintain the pH of said formulation or composition between 6.7 and
• the stable plasmid DNA liquid composition comprises a buffer solution in a concentration up to 2mM so as to maintain the pH of said formulation or composition between 7 and
• the molar concentration of the buffer solution is determined so as to exert the buffering effect within a limit and in a volume where the pH value is stabilized between 6 and 9, or between 6.2 and 8.5, preferably between 6.7 and 8, and most preferably between 7 and 7.5, and/or approximately +/- 0.3 from any of these values.
• the buffer solution may thus be added in concentration of less than 5mM.
• the stable plasmid DNA storage composition comprises traces of the buffer solution or a buffer solution in a very diluted concentration up to 2mM, and more preferably between ImM and 2mM.
• the buffer solution is present in a concentration less than ImM, between 250 ⁇ M and ImM, or between 400 ⁇ M and ImM, so as to maintain the pH of said formulation or composition between 6 and 9, or between 6.2 and 8.5, preferably between 6.7 and 8, and most preferably between 7 and 7.5, and/or approximately +/- 0.3 from any one or more of these values.
• the buffer solution is present in a concentration of up to 2mM, or between 1 and 2mM
• the buffer solution is present in a concentration of less than ImM. Most preferably the buffer solution is present as trace levels at a concentration as low as 250 ⁇ M and up to ImM. Trace levels of the buffer solution may be around 400 ⁇ M, and just sufficient to maintain the pH at the ranges indicated herein above.
• Buffer solutions that may be used in the compositions of the present invention consist either of an acid ⁇ ase system comprising Tris [tris(hydroxymethyl)-aminomethane], or lysine and an acid chosen from a strong acid (hydrochloric acid for example) or a weak acid (maleic acid, malic acid or acetic acid for example), or of an acid/base system comprising Hepes [2-(4-(2-hydroxyethylpiperazin)-l- yl)ethanesulphonic acid] and a strong base (sodium hydroxide for example), or phosphate buffers, such as sodium phosphate or potassium phosphate.
• an acid ⁇ ase system comprising Tris [tris(hydroxymethyl)-aminomethane], or lysine and an acid chosen from a strong acid (hydrochloric acid for example) or a weak acid (maleic acid, malic acid or acetic acid for example), or of an acid/base system comprising Hepes [2-(4-(2-
• the buffer solution may also comprise Tris/HCl, lysine/HCl, Tris/maleic acid, Tris/malic acid, Tris/acetic acid, or Hepes/sodium hydroxide.
• the Tris buffer is used in the stable plasmid DNA storage composition of the present invention.
• the plasmid DNA formulations according to the present invention exhibit an excellent stability both at 4 0 C and at room temperature (RT), e ⁇ g., 20 or 25 0 C.
• composition of the present invention may further comprise a saline excipient.
• Saline excipients that may used in the compositions of the present invention may comprise anions and cations selected from the group consisting of acetate, phosphate, carbonate, SO 2' 4 , Cl “ , Br “ , NO 3 " , Mg 2+ , Li + , Na + , K + , and NH 4 +, and any other salt or form of a pharmaceutical compound available or used previously.
• Preferred saline excipient is NaCl at a concentration between 100 and 200 mM, and preferably a concentration of around 15OmM.
• compositions according to the present invention are particularly useful for storing highly purified plasmid DNA or pharmaceutical grade plasmid DNA, that have very low levels of contaminating chromosomal DNA, RNA, protein, and endotoxins.
• Such highly purified plasmids DNA have less than about 0.01%; or 0.001%; or 0.0001% host cell RNA contaminant, or/and less than about .01%; or 0.001%; or 0.0001% host cell protein contaminant, and/or less than about .01%; or 0.001%; or 0.0001% host cell genomic DNA contaminant.
• the compositions according to the present invention may further comprise an adjuvant, such as for example a polymer selected among polyethylene glycol, a pluronic, or a polysorbate sugar, or alcohol.
• the present invention relates to a method of preserving plasmid DNA in a composition
• a method of preserving plasmid DNA in a composition comprising a) preparing a purified sample of plasmid DNA and b) combining said purified sample of plasmid DNA and a buffer solution in a concentration up to 2mM that maintains the pH of the resulting composition between 6.2 and 9.
• the pH is maintained between 6.5 and 8.5, preferably between 6.7 and 8, and most preferably between 7 and 7.5, and more particularly at around 7.2.
• the present invention also relates to a method of preserving plasmid DNA in a composition
• a method of preserving plasmid DNA in a composition comprising a) preparing a purified sample of plasmid DNA, b) combining said purified sample of plasmid DNA and a buffer solution in a concentration up to 2mM sufficient to maintain the pH of the resulting composition between 6 and 9; and c) storing the plasmid DNA.
• the method according to the present invention allows to store the plasmid DNA with at least 80% supercoiled plasmid DNA.
• the pH of the resulting composition may be maintained between 6.2 and 8.5 and approximately
• the pH of the resulting composition may be maintained between 6.7 and 8 approximately +/- 0.3, thereby permitting the plasmid DNA to be preserved at temperatures around +4 0 C to +25 0 C with depurination and nicking rates of less than 2% per month to less than 2% per year.
• the pH of the resulting composition may be maintained between 7 and 7.5 and approximately +/- 0.3 of one or more of these values, thereby permitting the plasmid DNA to be preserved at temperatures around +4 0 C to +25 0 C with depurination and nicking rates of less than 1% per month to less than 1% per year.
• the buffer solution is added to the composition of plasmid DNA in a concentration of up to 2mM, or between 1 and 2mM.
• the buffer solution is added to reach a concentration of less than ImM.
• the buffer solution is present as trace levels at a concentration as low as 250 ⁇ M and up to ImM. Trace levels of the buffer solution may be around 400 ⁇ M, and just sufficient to maintain the pH at the ranges indicated herein above.
• a saline excipient may further be added to the plasmid DNA and buffer solution.
• Preferred saline excipient is NaCl, at a concentration between 100 and 20OmM, and preferably around 15OmM.
• Plasmids DNA that are formulated in the compositions according to the present invention may be in an isolated form. They may be isolated via bacterial cell lysis and purification as described herein, or synthesized via automated nucleic acid synthesis equipment.
• polynucleotide encoding a polypeptide
• the polynucleotide may be a transgene, such a therapeutic gene, for example of a mammalian origin, such as a rodent or a human gene, and is operably linked to a promoter sequence.
• the polynucleotide which is inserted within the plasmid DNA may be of genomic origin, and therefore contain exons and introns as reflected in its genomic organization, or may be derived from complementary DNA.
• the polynucleotide can encode any of a variety of polypeptides, such as, without limitation, an immunogen peptide or protein, an angiogenesis factor, erythropoietin, adenosine deaminase, Factor VIII, Factor IX, dystrophin, ⁇ - globin, LDL receptor, CFTR, insulin, an anti-angiogenesis factor, a growth hormone, ⁇ l -antitrypsin, phenylalanine hydroxylase, tyrosine hydroxylase, an interleukin, and an interferon.
• an immunogen peptide or protein such as, without limitation, an immunogen peptide or protein, an angiogenesis factor, erythropoietin, adenosine deaminase, Factor VIII, Factor IX, dystrophin, ⁇ - globin, LDL receptor, CFTR, insulin, an anti-angiogenesis factor, a growth hormone, ⁇ l -antitry
• the plasmid DNA comprises a polynucleotide coding an angiogenesis factor, such as a FGF gene (FGF-I to FGF-22), VEGF, HGF, or HIF-I .
• angiogenesis factor such as a FGF gene (FGF-I to FGF-22), VEGF, HGF, or HIF-I .
• the polynucleotide can encode a siRNA, which may be used to inhibit expression of a target gene, e.g., where the gene expression is undesirable (e.g., the gene of a pathogen) or where the level of gene expression is undesirably high in a cell.
• Promoters suitable for use in various vertebrate systems are well known and include for example, RSV LTR, MPSV LTR, SV40, metallothionein promoter, and CMV IEP may advantageously be used.
• Plasmid DNA may include prokaryotic and eukaryotic vectors, and expression vectors, such as pBR322 and pUC vectors and their derivatives. They may incorporate various origins of replication, e.g., prokaryotic origins of replication, such as pMBl and CoIEl, or eukaryotic origins of replication, such as those facilitating replication in yeast, fungi, insect, and mammalian cells (e ⁇ g., SV40 ori).
• prokaryotic origins of replication such as pMBl and CoIEl
• eukaryotic origins of replication such as those facilitating replication in yeast, fungi, insect, and mammalian cells (e ⁇ g., SV40 ori).
• the insert may include DNA from any organism, but will preferably be of mammalian origin, and may include, in addition to a gene encoding a therapeutic protein, regulatory sequences such as promoters, enhancers, locus control regions, selectable genes, polylinkers for insertion of the transgene, leader peptide sequences, introns, polyadenylation signals, or combinations thereof.
• regulatory sequences such as promoters, enhancers, locus control regions, selectable genes, polylinkers for insertion of the transgene, leader peptide sequences, introns, polyadenylation signals, or combinations thereof.
• Selectable markers may be for examples antibiotic resistance gene, ej*., SupPhe tRNA, the tetracycline, resistance gene, kanamycin resistance gene, puromycin resistance gene, neomycin resistance gene, hygromycin resistance gene, and thymidine kinase resistance.
• the backbone of the plasmid advantageously permits inserts of fragments of mammalian, other eukaryotic, prokaryotic or viral DNA, and the resulting plasmid may be purified and used in vivo or ex vivo plasmid-based therapy.
• plasmid DNA with conditional origin of replication such as the pCOR plasmid which is described in US publication application 2003/1618445 is used.
• NVlFGF is a plasmid encoding an acidic Fibroblast Growth Factor or Fibroblast Growth Factor type 1 (FGF-I), useful for treating patients with end-stage peripheral arterial occlusive disease (PAOD) or with peripheral arterial disease (PAD).
• PAOD peripheral arterial occlusive disease
• PAD peripheral arterial disease
• the present invention provides with a composition as defined herein above for use in a method of treatment of a human body or animal body by therapy.
• the composition according to the present invention contains a pCOR plasmid encoding an angiogenic gene of the FGF or VEGF family for the treatment of cardiovascular disease such peripheral ischemia, peripheral arterial diseases, e.g., PAOD or PAD, critical limb ischemia (CLI), and intermittent claudication (IC).
• cardiovascular disease such peripheral ischemia, peripheral arterial diseases, e.g., PAOD or PAD, critical limb ischemia (CLI), and intermittent claudication (IC).
• the plasmid DNA comprises a polynucleotide encoding an immunizing peptide and may be used as a DNA vaccine.
• the present invention thus provides a composition for vaccination of humans or animals, thereby generating effective immunity against infectious agents, including intracellular viruses, and also against tumor cells.
• the plasmid DNA stable composition may be used as DNA vaccines to greatly enhance the immunogenicity of certain viral proteins, and cancer-specific antigens that normally elicit a poor immune response. They are useful for the induction of the induction of cytotoxic T cell immunity against poorly immunogenic viral proteins from the Herpes viruses, non-A, non-B hepatitis, and HIV.
• the plasmid DNA may encode immunity-conferring polypeptides, which can act as endogenous immunogens to provoke a humoral or cellular response, or both, or still for an antibody.
• antibody encompasses whole immunoglobulin of any class, chimeric antibodies and hybrid antibodies with dual or multiple antigen or epitope specificities, and fragments, such as F(ab) 2 , Fab', Fab and the like, including hybrid fragments. Also included within the meaning of "antibody” are conjugates of such fragments, and so-called antigen binding proteins (single chain antibodies) as described, for example, in U.S patent 4,704,692 (the content of which are hereby incorporated by reference).
• plasmid DNA comprising a polynucleotide coding for variable regions of an antibody may be used to produce antibody in situ.
• the antibody in turn would exert a therapeutic effect, for example, by binding a surface antigen associated with a pathogen.
• the encoded antibodies can be anti-idiotypic antibodies (antibodies that bind other antibodies) as described, for example, in U.S. Pat. No. 4,699,880.
• anti-idiotypic antibodies could bind endogenous or foreign antibodies in a treated individual, thereby to ameliorate or prevent pathological conditions associated with an immune response, e.g., in the context of an autoimmune disease.
• composition according to the present may thus be administered into humans or animals in vivo, allowing the plasmid DNA to be delivered to various cells of the animal body, including muscle, skin, brain, lung, liver, spleen, or to the cells of the blood.
• Delivery of the polynucleotides directly in vivo is preferably to the cells of muscle or skin. Injections may be done for example into muscle or skin using an injection syringe or a vaccine gun to provide effective immunization of the subject.
• the gene for an antigen being introduced into cells of the subject, the transfected cells, now expressing the antigen will be processed and presented to the immune system by the normal cellular pathways.
• Adjuvants or lymphokines may possibly be coinjected to further enhance immunization.
• the present plasmid DNA stable composition may be used for vaccination against viruses, or as DNA vaccine to treat latent viral infections, such as for example, Hepatitis B, HIV and members of the Herpes virus group, where the virus is maintained intracellular ⁇ in an inactive or partially active form.
• Plasmid DNA composition of the present invention may further be used for the treatment of malignant disease, to enhance the cellular immune response to a protein specific to the malignant state, an oncogene, a fetal antigen or an activation marker.
• Plasmids DNA that are formulated for long term storage according to the present invention are usually produced in bacterial cells which are then subject to lysis in order to release the cellular contents from which the pDNA is isolated.
• This process generally involves three steps comprising cell resuspension, cells lysis, neutralization and precipitation of host contaminants.
• Cell resuspension normally utilizes manual stirring or a magnetic stirrer, and a homogenizer or impeller mixer to resuspend cells in the resuspension buffer.
• Cell lysis may be carried out by manual swirling or magnetic stirring in order to mix the resuspended cells with lysis solution, consisting of lysozyme or diluted alkali (base), such as for example alkaline or potassium acetate (KOAc) and detergents; then holding the mixture at room temperature (20-25 degrees Celsius) or on ice for a period of time, such as 5 minutes, to complete lysis.
• lysis solution consisting of lysozyme or diluted alkali (base), such as for example alkaline or potassium acetate (KOAc) and detergents
• base such as for example alkaline or potassium acetate (KOAc) and detergents
• RNase is also generally added to degrade RNAs of the bacterial suspension.
• the third stage is neutralization and precipitation of host contaminants.
• Lysate from the second stage is normally mixed with a cold neutralization solution by gentle swirling or magnetic stirring to acidify the lysate before setting in ice for 10-30 minutes to facilitate the denaturation and precipitation of high molecular weight chromosomal DNA, host proteins, and other host molecules.
• alkaline lysis is performed and consists of mixing a suspension of bacterial cells with an alkaline lysis solution.
• the alkaline lysis solution consists of a detergent, e.g., sodium dodecyl sulfate (SDS), to lyse the bacterial cells and release the intracellular material, and an alkali, e.g., sodium hydroxide, to denature the proteins and nucleic acids of the cells (particularly gDNA and RNA). As the cells are lysed and the DNA is denatured, the viscosity of the solution rises dramatically.
• SDS sodium dodecyl sulfate
• an acidic solution e.g., potassium acetate (solution 3)
• solution 3 an acidic solution
• the potassium salt of dodecyl sulfate also precipitates, carrying away the proteins with which it is associated.
• the lysis technique may be conducted in batch mode, Le 13 where the different solutions are mixed by sequentially adding the solutions to vessels or tanks. After the solution containing the cell suspension has been mixed with the lysis solution, the viscoelastic alkaline lysate is mixed with the neutralization solution.
• Continuously mixing various cell-lysis solutions using a series of static mixers may be used as alternative to batch methods particularly when large scale plasmid productions are envisaged.
• a cell suspension solution and a cell-lysing solution are simultaneously added to a static mixer.
• the lysed cell solution that exits the first static mixer and a precipitating solution are then simultaneously added to a second static mixer.
• the solution that exits this second mixer contains the precipitated lysate and plasmids.
• Other continuous modes of lysing cells include use of a flow-through heat exchanger where the suspended cells are heated to 70-100 0 C. Following cell lysis in the heat exchanger, the exit stream is subjected to either continuous flow or batch-wise centrifugation during which the cellular debris and genomic DNA are precipitated, leaving the plasmid DNA in the supernatant.
• host cells are inoculated, le_. transformed with a plasmid DNA at exponential growth phase cells and streaked onto plates containing LB medium containing an antibiotic such as tetracycline.
• Single colonies from the plate are then inoculated each into 20 ml LB medium supplemented with the appropriate antibiotic tetracycline in separate sterile plastic Erlenmeyer flasks and grown for 12-16 hours at 37 0 C in a shaking incubator.
• One of these cultures was then used to inoculate 200 ml of sterile LB medium supplemented in a 2 L Erlenmeyer flasks.
• Host cell cultures and inoculation are well known in the art. Generally, host cells are grown until they reach high biomass and cells are in exponential growth in order to have a large quantity of plasmid DNA. Two distinct methods may be employed, le_., batch and fed-batch fermentation. Batch fermentation allows the growth rate to be controlled through manipulation of the growth temperature and the carbon source used.
• the term "batch fermentation” is a cell culture process by which all the nutrients required for cell growth and for production of plasmid contained in the cultured cells are in the vessel in great excess, such as for example up to 10-fold excess concentrations of nutrients, at the time of inoculation, thereby obviating the need to make additions to the sterile vessel after the post-sterilization additions, and the need for complex feeding models and strategies.
• the quantities of yeast extract in the batch medium enriched from 5 g/1 (as in LB medium) to 20 g/liter thus providing huge quantities of growth factors and nucleic acid precursors.
• the medium is also supplemented with ammonium sulfate (5 g/1) which acts as a source of organic nitrogen.
• feed-batch fermentation Another type of fermentation is fed-batch fermentation, in which the cell growth rate is controlled by the addition of nutrients to the culture during cell growth.
• fed-batch fermentation refers to a cell culture process in which the growth rate is controlled by carefully monitored additions of metabolites to the culture during fermentation.
• Fed-batch fermentation according to the invention permits the cell culture to reach a higher biomass than batch fermentation. Examples of fermentation process and exemplary rates of feed addition are described below for a 50 L preparation. However, other volumes, for example 10 L, 50 L, or greater than 500 L, also may be processed using the exemplary feed rates described below, depending on the scale of the equipment.
• Well-known lysis methods in the art include for example, flow-through heat lysis of microbial cells containing plasmid may be used. This process is described inter alia in the International publication WO 96/02658.
• the particular heat exchanger consisted of a 10 ft. x 0.25 inch O.D. stainless steel tube shaped into a coil. The coil is completely immersed into a constant high temperature water bath. The hold-up volume of the coil is about 50 mL. Thermocouples and a thermometer were used to measure the inlet and exit temperatures, and the water bath temperature, respectively.
• the product stream is pumped into the heating coil using a Masterflex peristaltic pump with silicone tubing. Cell lysate exited the coil and is then centrifuged in a Beckman J-21 batch centrifuge for clarification. After centrifugation, the plasmid DNA may be purified using the method of purification according to the present invention.
• Alternative cell lysis may make use of static mixers in series.
• a first static mixer for lysing the cells through a first static mixer and for precipitating the cell lysate though a second static mixer may be used as an alternative method for lysing the cell prior to the method of purifying plasmid DNA according to the present invention.
• Large volumes of cells can be gently and continuously lysed in-line using the static mixer and that other static mixers are placed in-line to accomplish other functions such as dilution and precipitation.
• Suitable static mixers useful in the method of the present invention include any flow through device referred to in the art as a static or motionless mixer of a length sufficient to allow the processes of the present invention.
• the static mixer would need to have a length which would provide enough contact time between the lysing solution and the cells to 5 cause the lysis of the subject cells during, passage through the mixer.
• Suitable static 5 mixers contain an internal helical structure which causes two liquids to come in contact with one another in an opposing rotational flow causing the liquids to mix together in a turbulent flow.
• Most preferred method or device for cell lysis comprises (a) a means for turbulent flow to rapidly mix a cell suspension (solution 1 in Figure 1) with a solution that lyses cells (solution 2 in Figure 1); and (b) a means for laminar flow to permit incubating a mixture formed in (a) without substantial agitation, wherein the mixture formed in (a) flows from the means for turbulent flow into the means for laminar flow. Additionally, this may comprise a means for adding a third solution that neutralizes the lysing solution (solution 3 in Figure 1), wherein the mixture incubated in (b) flows from the means for laminar flow into the means for adding a second solution.
• this process may be used to isolate plasmid DNA from cells comprising: (a) mixing the cells with an alkali lysing solution in the means for turbulent flow; and (b) neutralizing the alkaline lysing solution by adding an acidic solution.
• T tubes for mixing the cell suspension (solution 1) and the alkaline solution (solution 2) uniformly and very rapidly before the viscoelastic fluid appears, thereby providing a major advantage in limiting shear forces.
• T tubes have generally small diameter tubing, usually with a diameter inferior to 1 cm, preferably of around 2 and 8 mm, and more preferably of around 6mm, in order to increase contact time of mixed fluids, but that method does not make use of mixing induced by passage through the tube.
• Table 1 herein below shows variation of parameters BIa, BIb, B2 of the means for turbulent flow, laminar flow, and turbulent flow, respectively, and their corresponding flow rates Sl, S2, and S3 as displayed in Figure 1.
• Table 1 shows variation of parameters BIa, BIb, B2 of the means for turbulent flow, laminar flow, and turbulent flow, respectively, and their corresponding flow rates Sl, S2, and S3 as displayed in Figure 1.
• the process may use a mixer or injector with tubes instead of a T, which permits dispersion of the cells into the lysis solution. Accordingly, the mechanical stress on the fluids that pass through the tubes is greatly reduced compared to when the fluids are stirred, e ⁇ g., by paddles in tanks.
• the initial efficiency of mixing results in even greater efficiency in the seconds that follow, since this fluid does not yet have viscoelastic properties and the mixing realized by the small diameter tube is very efficient.
• the initial mixing is only moderate while the fluid becomes rapidly viscoelastic, resulting in considerable problems while flowing in the tube. This partial mixing results in lysis of only a portion of the cells and therefore can only release a portion of the plasmids before neutralization.
• Lysis may be divided into two phases during lysis, Phase I and Phase II. These two phases correspond to I) lysis of the cells and II) denaturation of nucleic acids, causing a major change in rheological behavior that results in a viscoelastic fluid. Adjusting the diameters of the tubes makes it possible to meet the needs of these two phases. Within a small diameter tube (BIa), mixing is increased. This is the configuration used for Phase I. Within a large diameter tube (BIb), the mixing (and thus the shear stress) is reduced. This is the configuration employed for Phase II.
• Preferred mixer used is the one called Ml, as depicted in Figure 2, but any T shaped device may also be used to provide dispersion of the cell suspension according to the present invention.
• One way of performing the lysis with this mixer is to inject solution 1 counter currently into the alkaline lysis solution through one or more small diameter orifices in order to obtain an efficient dispersion. Diameters of these orifices may be around 0.5 mm to 2 mm, and preferably about 1 mm in the configuration depicted.
• the mixture then exits mixer Ml to pass through a tube of small diameter (Figure 1) for a short time period (of about 2.5 sec). Combination of the diameter and flow time may be easily calculated to maintain a turbulent flow. Examples of variations of these parameters are provided in Table 1.
• tube diameter provides the inner diameter of the tube, not the outer diameter, which includes the thickness of the tube walls themselves. This brief residence time in the tube permits very rapid homogenization of solutions 1 and 2. Assuming that solution 1 and solution 2 are still Newtonian fluids during Phase I, the flow mode is turbulent during the homogenization phase. At the exit from this tube, solutions 1 and 2 are homogenized, and the lysis of cells in suspension starts. The homogenized mixture then passes through a second tube (BIb) of much larger diameter ( Figure 1), in which lysis of the cells and formation of the viscoelastic fluid occurs.
• BIb second tube of much larger diameter
• a contact time of about 1 to 3 min, around 2 min, and preferably of 1 min 20 sec may be sufficient to complete the cell lysis and to denature nucleic acids.
• the flow mode of the fluid may be laminar, promoting slow diffusion of SDS and sodium hydroxide toward cellular components.
• the lysate thus obtained and the neutralization solution 3 may then be mixed with a Y mixer called M2.
• the inside diameter of the Y mixer is around 4 to 15 mm, or around 6 to 10 mm, and may be of around 6mm or around 10 mm.
• the small diameter tube ej*., about 6 mm tube
• the neutralized solution is then collected in a harvesting tank.
• rapidly lowering the pH induces flocculate formation (Le,., formation of lumps or masses).
• the partially denatured plasmid renatures very quickly and remains in solution. The floes settle down gradually in the harvesting tank, carrying away the bulk of the contaminants.
• Continuous lysis may be used on its own or with additional processes. Any type of cells, le_., prokaryotic or eukaryotic, may be lysed with this process, for any purposes related to lysing, such as releasing desired plasmid DNA from target cells to be subsequently purified.
• This process of continuous alkaline lysis step may be performed on cells harvested from a fermentation which has been grown to a biomass of cells that have not yet reached stationary phase, and are thus in exponential growth (2-10 g dry weight/liter).
• the continuous alkaline lysis step may also be performed on cells harvested from a fermentation which has been grown to a high biomass of cells and are not in exponential growth any longer, but have reached stationary phase, with a cellular concentration of approximately 10-200 g dry weight per liter, and preferably 12-60 g dry weight per liter.
• Plasmids DNA may be purified using various methods before being formulated in the stable storage composition according to the present invention.
• Plasmid DNA purification methods are well known in the art. Generally, methods for isolating and purifying plasmid DNA from bacterial fermentations, consist of disrupting bacterial host cells containing the plasmid, as described above, and neutralizing the lysate with acetate neutralization to cause precipitation of host cell genomic DNA and proteins, which are then removed by, for example, centrifugation.
• the liquid phase contains the plasmid DNA which is alcohol precipitated and then subjected to isopycnic centrifugation using CsCl in the presence of ethidium bromide to separate the various forms of plasmid DNA, Le.., supercoiled, nicked circle, and linearized. Further extraction with butanol is required to remove residual ethidium bromide followed by DNA precipitation using alcohol. Additional purification steps follow to remove host cell proteins. These methods are generally suitable for small or laboratory scale plasmid preparations. Alternatives methods include for example size exclusion chromatography, chromatography on hydroxyapatite, and various chromatographic methods based on reverse phase or anion exchange.
• nucleic acids or plasmid DNA are introduced into humans or animals in a therapeutic context, highly purified pharmaceutical grade plasmid DNA are required, as such purified nucleic acid must meet drug quality standards of safety, potency and efficacy.
• Removal of contaminating endotoxins may be required particularly when plasmid DNA are purified from gram- negative bacterial sources that have high levels of endotoxins.
• endotoxins are generally lipopolysaccharides, or fragments thereof, that are components of the outer membrane of Gram- negative bacteria, and are present in the DNA preparation of the host cells and host cell membranes or macromolecules. They may cause inflammatory reactions, such as fever or sepsis in the host receiving the plasmid DNA.
• endotoxins may be a crucial and necessary step in the purification of plasmid DNA for therapeutic or prophylactic use.
• Endotoxin removal from plasmid DNA solutions primarily uses the negatively charged structure of the endotoxins.
• plasmid DNA also is negatively charged and hence separation is usually achieved with anion exchange resins which bind both these molecules and, under certain conditions, preferentially elute plasmid DNA while binding the endotoxins.
• nucleic acids free from contaminating endotoxins, which if administered to a patient could elicit a toxic response
• the plasmid DNA is preferably purified through a combination of chromatography steps, allowing to obtain a plasmid DNA preparation containing low levels, Ie ⁇ part per millions (ppm) of contaminating chromosomal DNA, RNA, protein, and endotoxins, and containing mostly closed circular form plasmid DNA. More preferably, purification methods which are described in the international publication WO95/026331 and in the international patent application No. PCT/EP2005/005213, are used for preparing plasmid DNA for applications in research and plasmid- based therapy, such as gene therapy and DNA vaccine.
• Purification methods comprises the use of triple helix affinity chromatography, which is preceded by or followed by at least one additional chromatography technique, optionally or typically as the final purification steps or at least at the end or near the end of the plasmid purification scheme.
• Triple helix affinity chromatography is used in combination with one or more chromatography step, such as ion exchange chromatography, hydrophobic interaction chromatography, gel permeation, or size exclusion chromatography, hydroxyapatite (type I and II) chromatography, reversed phase, and affinity chromatography. Any available affinity chromatography protocol involving nucleic acid separation can be adapted for use.
• anion exchange chromatography or any one or more of the other chromatography steps or techniques used can employ stationary phases, displacement chromatography methods, simulated moving bed technology, and/or continuous bed columns or systems.
• any one or more of the steps or techniques can employ high performance chromatography techniques or systems.
• the method preferably comprises purification steps including triple helix affinity chromatography with a further step of ion exchange chromatography and further may include hydrophobic interaction chromatography or gel permeation chromatography.
• the step of ion exchange chromatography may be both in fluidized bed ion exchange chromatography and axial and/or radial high resolution anion exchange chromatography.
• Most preferred method includes combination of ion exchange chromatography, triple helix affinity chromatography and hydrophobic interaction chromatography steps, occurring in that order. A lysate filtration or other flocculate removal may precede the first chromatography step.
• continuous lysis may be combined with the above-listed purification steps, and result in a high purity product containing pDNA. It may, for example, be combined with at least one of flocculate removal (such as lysate filtration, settling, or centrifugation), ion exchange chromatography (such as cation or anion exchange), triplex affinity chromatography, and hydrophobic interaction chromatography.
• flocculate removal such as lysate filtration, settling, or centrifugation
• ion exchange chromatography such as cation or anion exchange
• triplex affinity chromatography triplex affinity chromatography
• hydrophobic interaction chromatography hydrophobic interaction chromatography
• the method may also use further steps of size exclusion chromatography (SEC), reversed- phase chromatography, hydroxyapatite chromatography, and/or other available chromatography techniques, methods, or systems in combination with the steps described herein in accordance with the present application.
• SEC size exclusion chromatography
• reversed- phase chromatography hydroxyapatite chromatography
• hydroxyapatite chromatography hydroxyapatite chromatography
• a flocculate removal may be employed to provide higher purity to the resulting pDNA product. This step may be used to remove the bulk of precipitated material (flocculate).
• One mechanism of performing flocculate removal is through a lysate filtration step, such as through a 1 to 5 mm, and preferably a 3.5 mm grid filter, followed by a depth filtration as a polishing filtration step.
• Other methods of performing flocculate removal are through centrifugation or settling.
• Ion exchange chromatography may be employed to provide higher purity to the resulting pDNA product.
• Anion exchange may be selected depending on the properties of the contaminants and the pH of the solution.
• Anion exchange chromatography may be employed to provide higher purity to the resulting pDNA product.
• Anion exchange chromatography functions by binding negatively charged (or acidic) molecules to a support which is positively charged. The use of ion-exchange chromatography, then, allows molecules to be separated based upon their charge. Families of molecules (acidic, basic and neutral) can be easily separated by this technique. Stepwise elution schemes may be used, with many contaminants eluting in the early fractions and the pDNA eluted in the later fractions.
• Anion exchange is very efficient for removing protein and endotoxin from the pDNA preparation.
• packing material and method of preparing such material as well as process for preparing, polymerizing and functionalizing anion exchange chromatography and eluting and separating plasmid DNA there through are well known in the art.
• Compound to be used for the synthesis of base materials that are used for the packing material for anion exchange chromatography may be any compounds, if various functional groups that exhibit hydrophobicity or various ion exchange groups can be introduced by a post-reaction after the base materials are synthesized.
• monofunctional monomers examples include styrene, o- halomethylstyrene, m-halomethylstyrene, p-halomethylstyrene, o-haloalkylstyrene, m-haloalkylstyrene, p-haloalkylstyrene, ⁇ -methylstyrene, ⁇ -methyl-o-halomethylstyrene, ⁇ -methyl-m-halomethylstyrene, ⁇ - methyl-p-halomethylstyrene, ⁇ -methyl-o-haloalkylstyrene, ⁇ -methyl-m-haloalkylstyrene, ⁇ -methyl-p- haloalkylstyrene, o-hydroxymethylstyrene, m-hydroxymethylstyrene, p-hy droxy methyl sty rene, o- hydroxyalky
• Most preferred compounds are haloalkyl groups substituted on aromatic ring, halogens such as Cl, Br, I and F and straight chain and/or branched saturated hydrocarbons with carbon atoms of 2 to 15.
• polyfunctional monomers include divinylbenzene, trivinylbenzene, divinyltoluene, trivinyltoluene, divinylnaphthalene, trivinylnaphthalene, ethylene glycol dimethacrylate, ethylene glycol diacrylate, diethylene glycol dimethacrylate, diethylene glycol diacrylate, methylenebismethacrylamide, and methylenebisacrylamide.
• Preparation of the base material includes a first step wherein monofunctional monomer and polyfunctional monomer are weighed out at an appropriate ratio and precisely weighed-out diluent or solvent which are used for the purpose of adjusting the pores in particles formed and similarly precisely weighed-out polymerization initiator are added, followed by well stirring.
• the mixture is then submitted to a oil-in-water type suspension polymerization wherein the mixture is added into an aqueous solution dissolved suspension stabilizer weighed out precisely beforehand, and oil droplets with aiming size are formed by mixing with stirrer, and polymerization is conducted by gradually warming mixed solution.
• Ratio of monofunctional monomer to polyfunctional monomer is generally around 1 mol of monofunctional monomer, and around 0.01 to 0.2 mol of polyfunctional monomer so as to obtain soft particles of base material.
• a polymerization initiator is also not particularly restricted, and azobis type and/or peroxide type being used commonly are used.
• Suspension stabilizers such as ionic surfactants, nonionic surfactants and polymers with amphipathic property or mixtures thereof may also be used to prevent the aggregation among oil droplets themselves.
• the packing material to be used for ion exchange chromatography for purifying plasmid DNAs is preferable to have relatively large pore diameter, particularly within a range from 1500 to 4000 angstroms.
• Surface modification to introduce ion exchange groups to base materials is well known in the art.
• Two types of eluents may be used for the ion exchange chromatography.
• a first eluent containing low-concentration of salt and a second eluent containing high-concentration of salt may be used.
• the eluting method consists in switching stepwise from the first eluent to the second eluent and the gradient eluting method continuously changing the composition from the first eluent to the second eluent.
• Buffers and salts that are generally used in these eluents for ion exchange chromatography may be used.
• aqueous solution with concentration of buffer of 10 to 50 mM and pH value of 6 to 9 is particularly preferable.
• aqueous solution with 0,1 to 2M sodium salt added to eluent C is particularly preferable.
• sodium salts sodium chloride and sodium sulfate may be used.
• a chelating agent for bivalent metal ion may be used such as for example, ethylenediamine-tetraacetic acid, for inhibiting the degradation of plasmids due to DNA-degrading enzymes in the lysate of Escherichia coli.
• concentration of chelating agent for bivalent metal ion is preferably 0.1 to 100 mM.
• anion exchange matrices are suitable for use in the present invention, including but not limited to those available from POROS Anion Exchange Resins, Qiagen, Toso Haas, Sterogene, Spherodex, Nucleopac, and Pharmacia.
• the column (Poros II PI/M, 4.5 mm x 100) is initially equilibrated with 20 mM Bis/TRIS Propane at pH 7.5 and 0.7 M NaCl. The sample is loaded and washed with the same initial buffer. An elution gradient of 0.5 M to 0.85 M NaCl in about 25 column volumes is then applied and fractions are collected.
• Preferred anion exchange chromatography includes Fractogel TMAE HiCap.
• Triplex helix affinity chromatography is based on specific hybridization of oligonucleotides and a target sequence within the double-stranded DNA.
• oligonucleotides may contain the following bases: thymidine (T), which is capable of forming triplets with A.T doublets of double-stranded DNA (Rajagopal et al., Biochem 28 (1989) 7859); adenine (A), which is capable of forming triplets with A.T doublets of double-stranded DNA; guanine (G), which is capable of forming triplets with G.C doublets of double-stranded DNA; - protonated cytosine (C+), which is capable of forming triplets with G.C doublets of double-stranded DNA (Rajagopal et al., loc.
• T thymidine
• A adenine
• G guanine
• C+ protonated cytosine
• the oligonucleotide used comprises a cytosine-rich homopyrimidine sequence and the specific sequence present in the DNA is a homopurine-homopyrimidine sequence.
• cytosines makes it possible to have a triple helix which is stable at acid pH where the cytosines are protonated, and destabilized at alkaline pH where the cytosines are neutralized.
• Oligonucleotide and the specific sequence present in the DNA are preferably complementary to allow formation of a triple helix. Best yields and the best selectivity may be obtained by using an oligonucleotide and a specific sequence which are fully complementary.
• Preferred oligonucleotides have a sequence 5'-GAGGCTTCTTCTTCTT CTTCTTCTT-3' (GAGG(CTT) 7 (SEQ ID NO: 1), in which the bases GAGG do not form a triple helix but enable the oligonucleotide to be spaced apart from the coupling arm; the sequence (CTT) 7 .
• These oligonucleotides are capable of forming a triple helix with a specific sequence containing complementary units (GAA).
• the sequence in question can, in particular, be a region containing 7, 14 or 17 GAA units, as described in the examples.
• sequence 5'-AAGGGAGGGAGGA GAGG AA-3' (SEQ ID NO: 2).
• This sequence forms a triple helix with the oligonucleotides 5'-AAGGAGAGGAGGGAGGGAA-S' (SEQ ID NO: 3) or 5 l -TTGGTGTGGTGGGTGGGTT-3 1 (SEQ ID NO: 4).
• the oligonucleotide binds in an antiparallel orientation to the polypurine strand.
• These triple helices are stable only in the presence Of Mg 2+ (Vasquez et al., Biochemistry, 1995, 34, 7243-7251 ; Beal and Dervan, Science, 1991, 251 , 1360-1363).
• the specific sequence can be a sequence naturally present in the double-stranded DNA, or a synthetic sequence introduced artificially in the latter. It is especially advantageous to use an oligonucleotide capable of forming a triple helix with a sequence naturally present in the double-stranded DNA, for example in the origin of replication of a plasmid or in a marker gene. To this regard, it is known through sequence analyses that some regions of these DNAs, in particular in the origin of replication, could possess homopurine-homopyrimidine regions.
• oligonucleotides capable of forming triple helices with these natural homopurine-homopyrimidine regions advantageously enables the method of the invention to be applied to unmodified plasmids, in particular commercial plasmids of the pUC, pBR322, pSV, and the like, type.
• plasmids in particular commercial plasmids of the pUC, pBR322, pSV, and the like, type.
• homopurine-homopyrimidine sequences naturally present in a double-stranded DNA a sequence comprising all or part of the sequence 5'-CTTCCCGAAGGGAGAAAGG-S' (SEQ ID NO: 5) present in the origin of replication of E 1 coH plasmid CoIEl may be mentioned.
• the oligonucleotide forming the triple helix possesses the sequence: 5'-GAAGGGCTTCCCTCTTTCC ⁇ ' (SEQ ID NO: 6), and binds alternately to the two strands of the double helix, as described by Beal and Dervan (J. Am. Chem. Soc. 1992, 114, 4976-4982) and Jayasena and Johnston (Nucleic Acids Res. 1992, 20, 5279-5288).
• the sequence 5'-GAAAAAGGAAGAG-3' (SEQ ID NO: 7) of the plasmid pBR322 / ⁇ -lactamase gene may also be mentioned.
• pCOR plasmids are plasmids with conditional origin of replication and are inter alia described US 2004/142452 and US 2003/161844.
• ColEl-derived plasmids contain a 12-mer homopurine sequence (5'-AGAAAAAAAGGA-3 T ) (SEQ ID NO: 8) mapped upstream of the RNA-II transcript involved in plasmid replication (Lacatena et al., 1981, Nature, 294, 623).
• This sequence forms a stable triplex structure with the 12-mer complementary 5'-TCTTTTTTTCCT-S' (SEQ ID NO: 9) oligonucleotide.
• the pCOR backbone contains a homopurine stretch of 14 non repetitive bases (5'-AAGAAAAAAAAGAA-3') (SEQ ID NO: 10) located in the A+T-rich segment of the ⁇ origin replicon of pCOR (Levchenko et al., 1996, Nucleic Acids Res., 24, 1936).
• This sequence forms a stable triplex structure with the 14-mer complementary oligonucleotide 5'-TTCTTTTTTTTCTT-S' (SEQ ID NO: 11).
• the corresponding oligonucleotides 5'-TCTTTTTTTCCT-3' (SEQ ID NO: 8) and 5'-TTCTTTTTTTTCTT ⁇ ' (SEQ ID NO: 11) efficiently and specifically target their respective complementary sequences located within the origin of replication of either CoIEl ori or pCOR (ori ⁇ ).
• a single non-canonical triad (T*GC or C*AT) may result in complete destabilization of the triplex structure.
• an oligonucleotide capable of forming a triple helix with a sequence present in an origin of replication or a marker gene is especially advantageous, since it makes it possible, with the same oligonucleotide, to purify any DNA containing the said origin of replication or said marker gene. Hence it is not necessary to modify the plasmid or the double-stranded DNA in order to incorporate an artificial specific sequence in it.
• the oligonucleotides of the invention comprise the sequence (CCT) n , the sequence (CT) n or the sequence (CTT) n , in which n is an integer between 1 and 15 inclusive. It is especially advantageous to use sequences of the type (CT) n or (CTT) n .
• the Applicant showed, in effect, that the purification yield was influenced by the amount of C in the oligonucleotide. In particular, as shown in Example 7, the purification yield increases when the oligonucleotide contains fewer cytosines. It is understood that the oligonucleotides of the invention can also combine (CCT), (CT) or (CTT) units.
• the oligonucleotide used may be natural (composed of unmodified natural bases) or chemically modified.
• the oligonucleotide may advantageously possess certain chemical modifications enabling its resistance to or its protection against nucleases, or its affinity for the specific sequence, to be increased.
• Oligonucleotide is also understood to mean any linked succession of nucleosides which has undergone a modification of the skeleton with the aim of making it more resistant to nucleases.
• oligonucleotide phosphorothioates which are capable of forming triple helices with DNA (Xodo et al., Nucleic Acids Res., 1994, 22, 3322-3330), as well as oligonucleotides possessing formacetal or methylphosphonate skeletons (Matteucci et al., J. Am. Chem. Soc, 1991, JJl, 7767-7768), may be mentioned. It is also possible to use oligonucleotides synthesized with ⁇ anomers of nucleotides, which also form triple helices with DNA (Le Doan et al., Nucleic Acids Res., 1987, J_5, 7749-7760).
• phosphoramidate link Another modification of the skeleton is the phosphoramidate link.
• the N 3 -P 5 internucleotide phosphoramidate link described by Gryaznov and Chen, which gives oligonucleotides forming especially stable triple helices with DNA J. Am. Chem. Soc, 1994, U_6, 3143-3144
• the use of ribonucleotides, of 2'-O-methylribose, phosphodiester, etc. (Sun and Helene, Curr. Opinion Struct. Biol., 116, 3143-3144) may also be mentioned.
• the phosphorus-based skeleton may be replaced by a polyamide skeleton as in PNAs (peptide nucleic acids), which can also form triple helices (Nielsen et al., Science, 1991, 254, 1497-1500; Kim et al., J. Am. Chem. Soc, 1993, 115, 6477-6481), or by a guanidine-based skeleton, as in DNGs (deoxyribonucleic guanidine, Proc Natl. Acad. Sci. USA, 1995, 92, 6097-6101), or by polycationic analogues of DNA, which also form triple helices.
• PNAs peptide nucleic acids
• the thymine of the third strand may also be replaced by a 5-bromouracil, which increases the affinity of the oligonucleotide for DNA (Povsic and Dervan, J. Am. Chem. Soc, 1989, 11 1, 3059-3061).
• the third strand may also contain unnatural bases, among which there may be mentioned 7-deaza-2'-deoxyxanthosine (Milligan et al., Nucleic Acids Res., 1993, 21_, 327-333), l-(2-deoxy- ⁇ -D-ribofuranosyl)-3-methyl-5-amino- lH-pyrazolo[4,3-cflpyrimidin-7-one (Koh and Dervan, J. Am. Chem.
• oligonucleotide has the aim, more especially, of improving the interaction and/or affinity between the oligonucleotide and the specific sequence.
• a most advantageous modification according to the invention consists in methylating the cytosines of the oligonucleotide.
• the oligonucleotide thus methylated displays the noteworthy property of forming a stable triple helix with the specific sequence in pH ranges closer to neutrality (> 5). It hence makes it possible to work at higher pH values than the oligonucleotides of the prior art, that is to say at pH values where the risks of degradation of plasmid DNA are much smaller.
• the length of the oligonucleotide used in the method of the invention is between 5 and 30.
• An oligonucleotide of length greater than 10 bases is advantageously used.
• the length may be adapted by a person skilled in the art for each individual case to suit the desired selectivity and stability of the interaction.
• oligonucleotides according to the invention may be synthesized by any known technique. In particular, they may be prepared by means of nucleic acid synthesizers. Any other method known to a person skilled in the art may quite obviously be used. To permit its covalent coupling to the support, the oligonucleotide is generally functionalized.
• a thiol, amine or carboxyl terminal group at the 5' or 3' position may be modified by a thiol, amine or carboxyl terminal group at the 5' or 3' position.
• a thiol, amine or carboxyl group makes it possible, for example, to couple the oligonucleotide to a support bearing disulphide, maleimide, amine, carboxyl, ester, epoxide, cyanogen bromide or aldehyde functions.
• These couplings form by establishment of disulphide, thioether, ester, amide or amine links between the oligonucleotide and the support. Any other method known to a person skilled in the art may be used, such as bifunctional coupling reagents, for example.
• the oligonucleotide can contain an "arm" and a "spacer" sequence of bases.
• the use of an arm makes it possible, in effect, to bind the oligonucleotide at a chosen distance from the support, enabling its conditions of interaction with the DNA to be improved.
• the arm advantageously consists of a linear carbon chain, comprising 1 to 18 and preferably 6 or 12 (CH 2 ) groups, and an amine which permits binding to the column.
• the arm is linked to a phosphate of the oligonucleotide or of a "spacer" composed of bases which do not interfere with the hybridization.
• the "spacer” can comprise purine bases.
• the "spacer” can comprise the sequence GAGG.
• the arm is advantageously composed of a linear carbon chain comprising 6 or 12 carbon atoms.
• Triplex affinity chromatography is very efficient for removing RNA and genomic DNA.
• These can be functionalized chromatographic supports, in bulk or prepacked in a column, functionalized plastic surfaces or functionalized latex beads, magnetic or otherwise. Chromatographic supports are preferably used.
• the chromatographic supports capable of being used are agarose, acrylamide or dextran as well as their derivatives (such as Sephadex, Sepharose, Superose, etc.), polymers such as poly(styrene/divinylbenzene), or grafted or ungrafted silica, for example.
• the chromatography columns can operate in the diffusion or perfusion mode.
• a sequence containing several positions of hybridization with the oligonucleotide is especially advantageous to use, on the plasmid.
• the presence of several hybridization positions promotes, in effect, the interactions between the said sequence and the oligonucleotide, which leads to an improvement in the purification yields.
• CCT CCT
• CTT CCT
• CTT CCT
• CTT CTT
• CTT CCT
• CTT CTT
• a sequence carrying n+ 1 complementary motif thus affords two positions of hybridization with the oligonucleotide.
• the DNA sequence contains up to 1 1 hybridization positions, that is to say n+10 complementary motifs.
• the method according to the present invention can be used to purify any type of double-stranded DNA.
• An example of the latter is circular DNA, such as a plasmid, generally carrying one or more genes of therapeutic importance.
• This plasmid may also carry an origin of replication, a marker gene, and the like.
• the method of the invention may be applied directly to a cell lysate.
• the plasmid, amplified by transformation followed by cell culture is purified directly after lysis of the cells.
• the method of the invention may also be applied to a clear lysate, that is to say to the supernatant obtained after neutralization and centrifugation of the cell lysate. It may quite obviously be applied also to a solution prepurified by known methods.
• This method also enables linear or circular DNA carrying a sequence of importance to be purified from a mixture comprising DNAs of different sequences.
• the method according to the invention can also be used for the purification of double-stranded DNA.
• the cell lysate can be a lysate of prokaryotic or eukaryotic cells.
• prokaryotic cells the bacteria E. coH, B. subtilis, S 1 typhimurium or Strepomyces may be mentioned as examples.
• eukaryotic cells animal cells, yeasts, fungi, and the like, may be mentioned, and more especially Kluyveromyces or Saccharomyces yeasts or COS, CHO, C 127, NIH3T3, and the like, cells.
• the method of the present invention which includes at least a step of triplex affinity chromatography may be employed to provide higher purity to the resulting pDNA product.
• triplex affinity chromatography an oligonucleotide is bound to a support, such as a chromatography resin or other matrix.
• the sample being purified is then mixed with the bound oligonucleotide, such as by applying the sample to a chromatography column containing the oligonucleotide bound to a chromatography resin.
• the desired plasmid in the sample will bind to the oligonucleotide, forming a triplex.
• the bonds between the oligonucleotide and the plasmid may be Hoogsteen bonds.
• This step may occur at a pH ⁇ 5, at ⁇ high salt concentration for a contact time of 20 minutes or more.
• a washing step may be employed.
• cytosine deprotonation occurs in a neutral buffer, eluting the plasmid from the oligonucleotide-bound resin.
• Hydrophobic interaction chromatography uses hydrophobic moieties on a substrate to attract hydrophobic regions in molecules in the sample for purification. It should be noted that these HIC supports work by a "clustering" effect; no covalent or ionic bonds are formed or shared when these molecules associate. Hydrophobic interaction chromatography is beneficial as it is very efficiently removes open circular plasmid forms and other contaminants, such as gDNA, RNA, and endotoxin.
• Compound to be used for the synthesis of base materials that are used for the packing material for hydrophobic interaction chromatography may be any compounds, if various functional groups that exhibit hydrophobicity or various ion exchange groups can be introduced by a post-reaction after the base materials are synthetized.
• monofunctional monomers examples include styrene, o- halomethylstyrene, m-halomethylstyrene, p-halomethylstyrene, o-haloalkylstyrene, m-haloalkylstyrene, p-haloalkylstyrene, ⁇ -methylstyrene, ⁇ -methyl-o-halomethylstyrene, ⁇ -methyl-m-halomethylstyrene, ⁇ - methyl-p-halomethylstyrene, ⁇ -methyl-o-haloalkylstyrene, ⁇ -methyl-m-haloalkylstyrene, ⁇ -methyl-p- haloalkylstyrene, o-hydroxymethylstyrene, m-hydroxymethylstyrene, p-hydroxymethylstyrene, o- hydroxyalkylstyrene,
• polyfunctional monomers examples include divinylbenzene, trivinylbenzene, divinyltoluene, trivinyltoluene, divinylnaphthalene, trivinylnaphthalene, ethylene glycol dimethacrylate, ethylene glycol diacrylate, diethylene glycol dimethacrylate, diethylene glycol diacrylate, methylenebismethacrylamide, and methylenebisacrylamide.
• the base material is preferably prepared using relatively hydrophilic monomers, such as glycidyl methacrylate, glycidyl acrylate, hydroxyethyl acrylate, hydroxymethacrylate, and vinyl acetate.
• Preparation of the base material includes a first step wherein monofunctional monomer and polyfunctional monomer are weighed out at an appropriate ratio and precisely weighed-out diluent or solvent which are used for the purpose of adjusting the pores in particles formed and similarly precisely weighed-out polymerization initiator are added, followed by well stirring.
• the mixture is then submitted to a oil-in-water type suspension polymerization wherein the mixture is added into an aqueous solution dissolved suspension stabilizer weighed out precisely beforehand, and oil droplets with aiming size are formed by mixing with stirrer, and polymerization is conducted by gradually warming mixed solution.
• Ratio of monofunctional monomer to polyfunctional monomer is generally around 1 mol of monofunctional monomer, and around 0.01 to 0.2 mol of polyfunctional monomer so as to obtain soft particles of base material.
• the ratio of polyfunctional monomer may be increased to around 0.2 to 0.5 mol so as to obtain hard particles of base materials.
• Polyfunctional monomer alone may be used to obtain ever harder particules.
• a polymerization initiator is also not particularly restricted, and azobis type and/or peroxide type being used commonly are used.
• Suspension stabilizers such as ionic surfactants, nonionic surfactants and polymers with amphipathic property or mixtures thereof may also be used to prevent the aggregation among oil droplets themselves.
• the diameter of formed particles is generally around of 2 to 500 ⁇ m.
• Preferred diameter of the particles is comprised between 2 to 30 ⁇ m, and more preferably around 2 to 10 ⁇ m.
• it is around 10 to 100 ⁇ m and, when separating the aiming product from crude stock solution, it may be 100 to 500 ⁇ m, more preferably around 200 to 400 ⁇ m.
• the rotational speed of stirrer may be adjusted during polymerization. When particles with small diameter are needed, the number of revolutions may be increased and, when large particles are desired, the number of revolutions may be decreased.
• the diluent to be used is used for adjusting pores in formed particles, the selection of diluent is particularly important.
• the solvent to be used for polymerization adjustment is made by variously combining a solvent that is poor solvent for monomer with a solvent that is good solvent for monomer.
• the size of pore diameter may be selected appropriately depending on the molecular size of nucleic acids designed to separate, but it is preferable to be within a range of 500 to 4000 angstroms for the packing material for hydrophobic interaction chromatography and within a range from 1500 to 4000 angstroms for the packing material for ion exchange chromatography.
• the surface modification of the base material is important.
• Hydrophobic groups may be selected among long chain or branched, including saturated hydrocarbon groups or unsaturated hydrocarbon groups with carbon atoms of 2 to 20. Aromatic ring may also be contained in the hydrocarbon group.
• Hydrophobic groups may also be selected among compounds having the following formula:
• Hydrophobic groups may further include ether group of alkylene glycol with carbon atoms of 2 to 20, which consists of repeating units of 0 to 10, wherein the opposite end of functional group reacted with base material may be OH group left as it is or may be capped with alkyl group with carbon atoms of 1 to 4.
• hydrophobic groups may be used solely or in mixture to modify the surface.
• Chain of alkyl groups with carbon atoms of 6 to 20 carbon atoms are preferred for low hydrophobicity like plasmids.
• Long chain of alkyl groups having 2 to 15 carbon atoms for separating compounds with high hydrophobicity such as RNA originating from Escherichia coli and RNA in the cells of human and animals.
• Alkyl groups of 4 to 18 carbon atoms for separating compounds with relatively low hydrophobicity such as DNAs originating from Escherichia coli and DNAs in the cells of human and animals.
• compounds may be selected appropriately to modify the surface without being confined to said exemplification.
• the degree of hydrophobicity of packing material varies depending on the concentration of salt in medium or the concentration of salt in eluent for adsorption.
• the degree of hydrophobicity of packing material differs depending on the amount of the group introduced into the base material.
• the pore diameter of the base material for hydrophobic interaction chromatography is particularly preferable to be 500 to 4000 angstroms, but it can be selected appropriately from said range depending on the molecular size of nucleic acids desired to separate. In general, since the retention of nucleic acids on the packing material and the adsorption capacity (sample leading) differ depending on the pore diameter, it is preferable to use a base material with large pore diameter for nucleic acids with large molecular size and a base material with small pore diameter for nucleic acids with small molecular size.
• styrene base material may be reacted with hydrophobic group comprising long chain of alkyl groups, using halogen-containing compound and/or carbonyl halide and catalyst such as FeCl 3 , SnCl 2 or AlCl 3 , and utilizing Friedel-Craft reaction, it is possible to add directly to aromatic ring in base material as dehalogenated compound and/or acylated compound.
• the base material being particle containing halogen group
• compounds with OH contained in functional group to be added like butanol, and utilizing Williamson reaction with alkali catalyst such as NaOH or KOH, it is possible to introduce the functional group through ether bond.
• the functional group desired to add being amino group-containing compound, like hexylamine
• alkali catalyst such as NaOH or KOH
• the base material containing OH group inversely, if introducing epoxy group, halogen group or carbonyl halide group beforehand into the functional group desired to add, it is possible to introduce the functional group through ether or ester bond.
• the base material containing epoxy group if reacting with compound with OH group or amino group contained in the functional group desired to add, it is possible to introduce the functional group through ether or amino bond.
• the functional group desired to add containing halogen group it is possible to add the functional group through ether bond using acid catalyst. Since the proportion of functional group to be introduced into base material is influenced by the hydrophobicity of subject product desired to separate, it cannot be restricted, but, in general, packing material with around 0.05 to 4.0 mmol of functional group added per 1 g of dried base material is suitable.
• Base material may also be porous silica gel.
• a method of manufacturing silica gel comprise silane coupling using a compound such as alkyltrimethoxysilane directly onto particles manufactured according to the method described in "Latest High-Speed Liquid Chromatography", page 289 ff. (written by Toshio Nambara and Nobuo Ikegawa, published by Tokyo Hirokawa Bookstore in 1988).
• a functional group Prior or after coupling the silane using epoxy group-containing silane coupling agent, a functional group may be added according to the method aforementioned. Proportion of functional group that is introduced around 0.05 to 4.0 mmol of functional group added per 1 g of dried base material is suitable.
• Eluents are used in the hydrophobic interaction chromatography separation or purification step.
• eluents Two types are used. One eluent contains high-concentration of salt, while a second eluent contains low-concentration of salt.
• the eluting method comprises switching stepwise from an eluent having high concentration of salt to an eluent having a low concentration of salt and the gradient eluting method continuously changing the composition from one eluent to another may be used.
• buffers and salts generally used for the hydrophobic interaction chromatography can be used.
• eluent containing high-concentration of salt aqueous solution with salt concentration of 1.0 to 4.5M and pH value of 6 to 8 is particularly preferable.
• aqueous solution with salt concentration of 0.01 to 0.5M and pH value of 6 to 8 is particularly preferable salts.
• ammonium sulfate and sodium sulfate may be used as salts.
• the hydrophobic interaction chromatography plasmid DNA purification step may be conducted by combining a packing material introduced the functional group with weak hydrophobicity with a packing material introduced the functional group with strong hydrophobicity in sequence.
• medium cultured Escherichia coli contain in large quantity, various components different in hydrophobicity such as polysaccharides, Escherichia coli genome DNA, RNAs plasmids and proteins. It is also known that there are differences in the hydrophobicity even among nucleic acids themselves. Proteins that become impurities have higher hydrophobicity compared with plasmids.
• hydrophobic interaction chromatography resins are available commercially, such as Fractogel propyl, Toyopearl, Source isopropyl, or any other resins having hydrophobic groups. Most preferred resins are Toyopearl bulk polymeric media. Toyopearl is a methacrylic polymer incorporating high mechanical and chemical stability. Resins are available as non-functionalized "HW" series resins and may be derivatized with surface chemistries for ion exchange chromatography or hydrophobic interactions. Four types of Toyopearl HIC resins featuring different surface chemistry and levels of hydrophobicity may be used.
• Toyopearl HIC resins increases through the series: Ether, Phenyl, Butyl, and Hexyl. Structures of preferred Toyopearl HIC resins, Le.., Toyopearl HW-65 having 1000 angstroms pore diameter are showed below:
• Toyopearl resins may have various particle size grade.
• Toyopearl 650C have a particle size of around 50 to 150 ⁇ m, preferably around lOO ⁇ m
• Toyopearl 650M have a particle size of around 40 to 90 ⁇ m, preferably around 65 ⁇ m
• Toyopearl 650S have a particle size of around 20 to 50 ⁇ m, preferably around 35 ⁇ m. It is well known that particle size influences resolution, Ie.., resolution improves from C to M to S particle size grade, and thus increases with smaller particle sizes.
• Toyopearl resin used in the HIC chromatography step within the process of separation and purification of the plasmid DNA according to the present invention is Toyopearl butyl- 650S which is commercialized by Tosoh Bioscience.
• a further diafiltration step may be performed.
• Standard, commercially available diafiltration materials are suitable for use in this process, according to standard techniques known in the art.
• a preferred diafiltration method is diafiltration using an ultrafiltration membrane having a molecular weight cutoff in the range of 30,000 to 500,000, depending on the plasmid size. This step of diafiltration allows for buffer exchange and concentration is then performed.
• the eluate is concentrated 3- to 4-fold by tangential flow filtration (membrane cut-off, 30 kDa) to a target concentration of about 2.5 to 3.0 mg/mL and the concentrate is buffer exchanged by diafiltration at constant volume with 10 volumes of saline and adjusted to the target plasmid concentration with saline.
• the plasmid DNA concentration is calculated from the absorbance at 260 nm of samples of concentrate. Plasmid DNA solution is filtered through a 0.2 ⁇ m capsule filter and divided into several aliquots, which are stored in containers in a cold room at 2-8°C until further processing. This yields a purified concentrate with a plasmid DNA concentration of supercoiled plasmid is around 70%, 75%, 80%, 85%, 90%, 95%, and preferably 99%. The overall plasmid recovery with this process is at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, and 80%, with an average recovery of 60 %.
• Such diafiltration step is conducted according the following conditions: buffer for step a) and for step b) are used: i) a first diafiltration (step a) against 12.5 to 13.0 volumes of 50 mM Tris/HCl, 150 mM NaCl, pH
• the plasmid DNA composition which is used contain purified plasmid DNA that is essentially free of contaminants or in the range of sub-ppm contaminants and thus is pharmaceutical grade DNA.
• the pharmaceutically grade plasmid DNA composition can comprise sub-ppm ( ⁇ 0.0001 %, i.e. ⁇ 0.0001 mg per 100 mg of plasmid DNA) gDNA, RNA, and protein contaminants
• the pharmaceutical grade plasmid DNA composition can comprise less than about 0.01%, or less than 0.001%, and preferably less than 0.0001%, or preferably less than 0.00008% ( ⁇ 0.0008%, i.e.
• the pharmaceutical grade plasmid DNA composition can comprise less than about 0.01%, or less than 0.001%, and preferably less than 0.0001%, or preferably less than 0.00002% ( ⁇ 0.0002%, i.e.
• the pharmaceutical grade plasmid DNA composition can comprise a plasmid DNA preparation that contains less than about 0.0001%, and most preferably less than 0.00005% ( ⁇ 0.00005%, i.e. ⁇ 0.00005 mg per 100 mg of plasmid DNA) of host cell protein contaminants.
• the pharmaceutical grade plasmid DNA composition can also comprise a plasmid DNA preparation that contains less than 0.1 EU/mg endotoxins.
• the pharmaceutical grade plasmid DNA composition thus contains predominant circular in form, and more precisely contains more than 80%, 85%, 90%, 95%, or 99% of closed circular form plasmid DNA.
• the pharmaceutical composition may have a detectable level of host cell genomic DNA of less than about 0.01% and less than about 0.001% host cell RNA can be included in the invention.
• the pharmaceutical grade plasmid DNA composition can have less than about 0.00008% host cell genomic DNA and less than about 0.00002% host cell RNA and less than about 0.00005% host cell protein.
• any combination of the purity levels noted above can be employed for any particular pharmaceutical grade plasmid DNA composition under the invention.
• the compositions can also comprise other pharmaceutically acceptable components, buffers, stabilizers, or compounds for improving gene transfer and particularly plasmid DNA transfer into a cell or organism.
• Plasmid DNA so obtained may then be formulated according to the present invention in NaCl as saline excipient and an appropriate concentration of Tris buffer so as to maintain or control the pH value between 6.2 and 9, preferably between 6.5 and 8, more preferably 7 and 7.5.
• Plasmid DNA formulations according to the present application are particularly useful as they plasmid DNA may surprisingly be stored in a stable non-degradable form in these conditions for prolonged period of time at 5 0 C and up to 25 0 C, that is at room temperature.
• the purified plasmid DNA is present in a solution with less than or about 0.1
• a pharmaceutical grade plasmid DNA composition comprises sub-ppm ( ⁇ 0.00001 %) host cell gDNA, RNA, and protein contaminants. More precisely, the pharmaceutical grade plasmid DNA composition that is essentially free of detectable gDNA, RNA, and protein contaminants.
• the pharmaceutical grade plasmid DNA composition is substantially free of detectable bacterial host chromosomal DNA, and thus comprises less than about 0.01%, or less than about 0.001%, or less than about 0.0001%, or preferably less than 0.00008% of chromosomal DNA or genomic DNA. Further, the pharmaceutical grade plasmid DNA composition that is substantially free of detectable host cell RNA, and more precisely, comprises less than about 0.01%, or less than 0.001%, and preferably less than 0.0001%, or preferably less than 0.00002% of host cell RNA contaminants. Further, the pharmaceutical grade plasmid DNA composition is substantially free of detectable host cell protein contaminants, and more precisely less than about 0.0001%, and most preferably less than 0.00005% host cell protein contaminants.
• the pharmaceutical grade plasmid DNA composition that is substantially free of measurable endotoxin contaminants, and more precisely less than 0.1 EU/mg endotoxins.
• the plasmid DNA is present in substantially supercoiled form, and more precisely comprises about or more than 99% of closed circular form plasmid DNA.
• a step of sterile filtration before filling of vials with the purified plasmid DNA may be performed.
• Vial of purified plasmid DNA obtainable by these methods are also provided.
• Purification of any types of vectors having various sizes may be performed.
• the size range of plasmid DNA that may be separated is from approximately 5 kb to approximately 50 kb, preferably 15 kb to 50 kb, which DNA includes a vector backbone of approximately 3 kb, a therapeutic gene and associated regulatory sequences.
• a vector backbone useful in the invention may be capable of carrying inserts of approximately 10-50 kb or larger.
• the insert may include DNA from any organism, but will preferably be of mammalian origin, and may include, in addition to a gene encoding a therapeutic protein, regulatory sequences such as promoters, poly adenylation sequences, enhancers, locus control regions, etc.
• the gene encoding a therapeutic protein may be of genomic origin, and therefore contain exons and introns as reflected in its genomic organization, or it may be derived from complementary DNA.
• Such vectors may include for example vector backbone replicatable with high copy number replication, having a polylinker for insertion of a therapeutic gene, a gene encoding a selectable marker, eg., SupPhe tRNA, the tetracycline kanamycin resistance gene, and is physically small and stable.
• the vector backbone of the plasmid advantageously permits inserts of fragments of mammalian, other eukaryotic, prokaryotic or viral DNA, and the resulting plasmid may be purified and used in vivo or ex vivo plasmid-based therapy.
• Vectors having relatively high copy number Le., in the range of 20-40 copies/cell up to 1000-2000 copies/cell, may be separated and purified by the method according to the present invention.
• a vector that includes the pUC origin of replication is preferred according to the method of the invention.
• the pUC origin of replication permits more efficient replication of plasmid DNA and results in a tenfold increase in plasmid copy number/cell over, e.g., a pBR322 origin.
• plasmid DNA with conditional origin of replication or pCOR as described in US 2003/1618445 may be separated by the process according to the present invention.
• the resulting high copy number greatly increases the ratio of plasmid DNA to chromosomal DNA, RNA, cellular proteins and co-factors, improves plasmid yield, and facilitates easier downstream purification.
• any vector plasmid DNA
• Representative vectors include but are not limited to NVl FGF plasmid.
• NVlFGF is a plasmid encoding an acidic Fibroblast Growth Factor or Fibroblast Growth Factor type 1 (FGF-I), useful for treating patients with end-stage peripheral arterial occlusive disease (PAOD) or with peripheral arterial disease (PAD).
• FGF-I Fibroblast Growth Factor type 1
• PAOD peripheral arterial occlusive disease
• PAD peripheral arterial disease
• Camerota et al. J Vase. Surg., 2002, 35, 5:930-936 describes that 51 patients with unreconstructible end-stage PAD, with pain at rest or tissue necrosis, have been intramuscularly injected with increasing single or repeated doses of NVlFGF into ischemic thigh and calf.
• Various parameters such as transcutaneous oxygen pressure, ankle and toe brachial indexes, pains assessment, and ulcer healing have been subsequently assessed.
• the plasmid DNA composition may further comprise at least one polymer for improving plasmid DNA transfer into a cell.
• the plasmid DNA composition may also comprise a pharmaceutically acceptable vehicle or excipient.
• the plasmid DNA composition may be formulated for delivery by injection, intravenous injection, intramuscular injection, intratumoral injection, small particle bombardment, or topical application to a tissue.
• the plasmid DNA within these compositions is substantially in the form of supercoiled closed circle DNA.
• Host cells useful according to the invention may be any bacterial strain, Le ⁇ both Gram positive and Gram negative strains, such as E. coli and Salmonella Typhimurium or Bacillus that is capable of maintaining a high copy number of the plasmids described above; for example 20-200 copies.
• E. coli host strains may be used according to the invention and include HBlOl, DHl, and DH5 ⁇ F, XAC-I and XAC-lpir 116, TEX2, and TEX2pir42 (WO04/033664).
• Strains containing the F plasmid or F plasmid derivatives are generally not preferred because the F plasmid may co-purify with the therapeutic plasmid product.
• Nucleotide sequences were determined by the chain termination method according to the protocol already published (Ausubel et al., 1987).
• DNA fragments are incubated in a buffer comprising 50 mM Tris-HCl pH 7.4, 10 mM MgCl 2 , 10 mM DTT, 2 mM ATP in the presence of phage T4 DNA ligase (Biolabs).
• Oligonucleotides are synthesized using phosphoramidite chemistry with the phosphoramidites protected at the ⁇ position by a cyanoethyl group (Sinha, N.D., J. Biernat, J. McManus and H. K ⁇ ster,
• Ligated DNAs or DNAs to be tested for their efficacy of transformation are used to transform the following strain rendered competent:
• LB culture medium is used for the growth of E. coU strains (Maniatis et al., 1982). Strains are incubated at 37 0 C. Bacteria are plated out on dishes of LB medium supplemented with suitable antibiotics.
• Non-Newtonian fluid The two types of non-Newtonian fluids most commonly encountered in industry are Bingham and Ostwald de Waele.
• Re N is the generalized Reynolds number
• Re N (1 / (2 n - 3 )) x (n / 3n +1)" x ((p x D n x w 2"n ) / m )
• D inside diameter of the cross section
• p volumetric mass of the fluid (kg/m 3 )
• w spatial velocity of the fluid
• n flow behavior index (dimensionless)
• m fluid consistency coefficient (dyn . s n / cm 2 )
• n and m are determined empirically (study of rheological behavior).
• Equation (1) f(inside diameter, ⁇ , p, and u) since n and m are functions of ⁇ .
• Re (u x D x p) / ⁇ (2)
• p Volumetric mass of the fluid (kg/m 3 )
• D inside diameter of the cross section (m)
• n and m may be determined from the study of the rheological behavior of the fluids and used to determine the right characteristics of the tubes.
• the duration of the agitation which in some embodiments of the present invention is obtained by adjusting the length of the coils.
• the diameter of the tubes or the fluid velocity does not appear to dominate in Equation (1) for a non-Newtonian fluid (data not shown). In other words, it does not seem to be more effective to alter the diameter than it is to alter the flow rate if equation (1) is used for calculations within BIb and in B2. Where high flow rates are desirable, the diameter can be varied along with the flow rate.
• BIa fine-tuning the mixing at the beginning of lysis: convection phenomenon (macromixing).
• BIb letting denaturation occur plus diffusion phenomenon (micromixing).
• Example 2 We can break down the CL system into 5 steps.
• the configuration is as follows:
• - Solution 1 EDTA 10 mM, glucose (GIc) 9 g/1 and Tris HCl 25 mM, pH 7.2.
• - Solution 2 SDS 1 % and NaOH 0.2 N.
• BIa 3 m long, 6 mm diameter, 2.5 sec residence time
• the process of the present invention provides an advantage in terms of efficiency, summarized as: dispersion, brief violent mixing, and gentle mixing by diffusion. Using the process of the present invention, the number of cells lysed is increased and therefore the quantity of plasmid DNA recovered is increased.
• the idea of diffusion is especially important because of the difficulty of mixing these fluids due to their properties, in particular the viscoelasticity.
• the process of the present invention makes it possible to limit shear stress and therefore to limit fragmentation of gDNA, facilitating its removal during subsequent chromatographic purification.
• solution 3 which may be cooled down to 4°C.
• process of the invention uses:
• Table 5 gives the results obtained in comparative tests to show the advantages of our continuous lysis process compared to batch lysis.
• the column used is a 1 ml HiTrap column activated with NHS (N-hydroxysuccinimide, Pharmacia) connected to a peristaltic pump (output ⁇ 1 ml/min.
• NHS N-hydroxysuccinimide, Pharmacia
• the specific oligonucleotide used possesses an NH 2 group at the 5' end, its sequence is as follows: 5'-GAGGCTTCTTCTTCTTCTTCTTCTT ⁇ ' (SEQ ID NO: 1)
• the buffers used in this example are the following:
• Coupling buffer 0.2 M NaHCO 3 , 0.5 M NaCl, pH 8.3.
• Buffer A 0.5 M ethanolamine, 0.5 M NaCl, pH 8.3.
• Buffer B 0.1 M acetate, 0.5 M NaCl, pH 4.
• the column is washed with 6 ml of 1 mM HCl, and the oligonucleotide diluted in the coupling buffer (50 nmol in 1 ml) is then applied to the column and left for 30 minutes at room temperature.
• the column is washed three times in succession with 6 ml of buffer A and then 6 ml of buffer B.
• the oligonucleotide is thus bound covalently to the column through a CONH link.
• the column is stored at 4 0 C in PBS, 0.1 % NaN 3 , and may be used at least four times.
• oligonucleotide 4817 5'-GATCCGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAA GAAGAAGG-3' (SEQ ID NO: 13) and oligonucleotide 4818 5'-AATTCCTTCTT
• oligonucleotides when hybridized and cloned into a plasmid, introduce a homopurine-homopyrimidine sequence (GAA) n (SEQ ID NO: 15) into the corresponding plasmid, as described above.
• GAA homopurine-homopyrimidine sequence
• the sequence corresponding to these two hybridized oligonucleotides is cloned at the multiple cloning site of plasmid pBKS+ (Stratagene Cloning System, La Jolla CA), which carries an ampicillin-resistance gene.
• the oligonucleotides are hybridized in the following manner: one ⁇ g of these two oligonucleotides are placed together in 40 ml of a final buffer comprising 50 mM Tris-HCl pH 7.4, 10 mM MgCl 2 . This mixture is heated to 95°C and then placed at room temperature so that the temperature falls slowly. Ten ng of the mixture of hybridized oligonucleotides are ligated with 200 ng of plasmid pBKS+ (Stratagene Cloning System, La Jolla CA) digested with BamHI and EcoRI in 30 ⁇ l final. After ligation, an aliquot is transformed into DH5a.
• plasmid pBKS+ Stratagene Cloning System, La Jolla CA
• the transformation mixtures are plated out on L medium supplemented with ampicillin (50 mg/1) and X-gal (20 mg/1).
• the recombinant clones should display an absence of blue colouration on this medium, contrary to the parent plasmid (pBKS+) which permits ⁇ -complementation of fragment ⁇ of E. coli /?-galactosidase.
• pBKS+ parent plasmid
• Plasmid pXL2563 is purif ed according to Wizard Megaprep kit (Promega Corp. Madison, WI) according to the supplier's recommendations. This plasmid DNA preparation is used in examples described below.
• Plasmid pXL2563 is purified on the HiTrap column coupled to the oligonucleotide, described in 1.1., from a solution also containing plasmid pBKS+.
• the buffers used in this purification are the following:
• Buffer F 2 M NaCl, 0.2 M acetate, pH 4.5 to 5.
• Buffer E 1 M Tris-HCl, pH 9, 0.5 mM EDTA.
• the column is washed with 6 ml of buffer F, and the plasmids (20 ⁇ g of pXL2563 and 20 ⁇ g of pBKS+ in 400 ⁇ l of buffer F) are applied to the column and incubated for 2 hours at room temperature.
• the column is washed with 10 ml of buffer F and elution is then carried out with buffer E.
• the plasmids are detected after electrophoresis on 1 % agarose gel and ethidium bromide staining. The proportion of the plasmids in the solution is estimated by measuring their transforming activity on E. coli.
• oligonucleotide is modified at the 5' end with an amine group linked to the phosphate of the spacer by an arm containing 6 carbon atoms (Modified oligonucleotide Eurogentec SA, Belgium).
• Plasmid pXL2563 is purified using the Wizard Megaprep kit (Promega Corp., Madison, WI) according to the supplier's recommendations.
• the buffers used in this example are the following:
• Buffer F 0-2 M NaCl, 0.2 M acetate, pH 4.5 to 5.
• Buffer E 1 M Tris-HCl pH 9, 0.5 mM EDTA.
• the column is washed with 6 ml of buffer F, and 100 ⁇ g of plasmid pXL2563 diluted in 400 ⁇ l of buffer F are then applied to the column and incubated for 2 hours at room temperature.
• the column is washed with 10 ml of buffer F and elution is then carried out with buffer E.
• the plasmid is quantified by measuring optical density at 260 nm.
• binding is carried out in a buffer whose molarity with respect to NaCl varies from 0 to 2 M (buffer F).
• the purification yield decreases when the molarity of NaCl falls.
• the pH of the binding buffer can vary from 4.5 to 5, the purification yield being better at 4.5.
• another elution buffer of basic pH elution is thus carried out with a buffer comprising 50 mM borate, pH 9, 0.5 mM EDTA.
• oligonucleotide S'-GAGGCTTCTTCTTCTTCTTCTTCTT-S' (SEQ ID NO: 1) to the column is carried out as described in Example 3.
• Plasmid pXL2563 is purified using the Wizard Megaprep kit (Promega Corp., Madison, WI) according to the supplier's recommendations.
• the buffers used in this example are the following:
• Buffer F 0.1 M NaCl, 0.2 M acetate, pH 5.
• Buffer E 1 M Tris-HCl pH 9, 0.5 mM EDTA.
• the column is washed with 6 ml of buffer F, and 100 ⁇ g of plasmid pXL2563 diluted in 400 ⁇ l of buffer F are then applied to the column and incubated for one hour at room temperature.
• the column is washed with 10 ml of buffer F and elution is then carried out with buffer E.
• the content of genomic or chromosomal E. coli DNA present in the plasmid samples before and after passage through the oligonucleotide column is measured.
• This genomic DNA is quantified by PCR using primers in the E. coli galK gene. According to the following protocol: The sequence of these primers is described by Debouck et al. (Nucleic Acids Res. 1985, H,_l 841-1853):
• the reaction medium comprises, in 25 ⁇ l of PCR buffer (Promega France, Charbonnieres): 1.5 mM MgCl 2 ; 0.2 mM dXTP (Pharmacia, Orsay); 0.5 ⁇ M primer; 20 U/ml Taq polymerase (Promega).
• the reaction is performed according to the sequence: - 5 min at 95 0 C - 30 cycles of 10 sec at 95 0 C 30 sec at 6O 0 C 1 min at 78 0 C - 10 min at 78 0 C.
• the amplified DNA fragment 124 base pairs in length is separated by electrophoresis on 3 % agarose gel in the presence of SybrGreen I (Molecular Probes, Eugene, USA), and then quantified by reference to an Ultrapur genomic DNA series from E. coH strain B (Sigma, ref D4889).
• This example describes plasmid DNA purification from a clear lysate of bacterial culture, on the so-called "miniprep" scale: 1.5 ml of an overnight culture of DH5 ⁇ strains containing plasmid pXL2563 are centrifuged, and the pellet is resuspended in 100 ⁇ l of 50 mM glucose, 25 mM Tris-HCl, pH 8, 10 mM EDTA. 200 ⁇ l of 0.2 M NaOH, 1 % SDS are added, the tubes are inverted to mix, 150 ⁇ l of 3 M potassium acetate, pH 5 are then added and the tubes are inverted to mix.
• plasmid After centrifugation, the supernatant is recovered and loaded onto the oligonucleotide column obtained as described in Example 1. Binding, washes and elution are identical to those described in Example 3. Approximately 1 ⁇ g of plasmid is recovered from 1.5 ml of culture. The plasmid obtained, analysed by agarose gel electrophoresis and ethidium bromide staining, takes the form of a single band of "supercoiled" circular DNA. No trace of high molecular weight (chromosomal) DNA or of RNA is detectable in the plasmid purified by this method.
• Example 6 This example describes a plasmid DNA purification experiment carried out under the same conditions as Example 5, starting from 20 ml of bacterial culture of DH5 ⁇ strains containing plasmid pXL2563. The cell pellet is taken up in 1.5 ml of 50 mM glucose, 25 mM Tris-HCl, pH 8, 10 mM EDTA. Lysis is carried out with 2 ml of 0.2 M NaOH, 1 % SDS, and neutralization with 1.5 ml of 3 M potassium acetate, pH 5.
• the DNA is then precipitated with 3 ml of 2-propanol, and the pellet is taken up in 0.5 ml of 0.2 M sodium acetate, pH 5, 0.1 M NaCl and loaded onto the oligonucleotide column obtained as described in the above Example. Binding, washing of the column and elution are carried out as described in the above Example, except for the washing buffer, the molarity of which with respect to NaCl is 0.1 M.
• the plasmid contains a cassette containing the cytomegalovirus promoter, the gene coding for luciferase and the homopurine-homopyrimidine sequence (GAA) )7 (SEQ ID NO: 15) originating from plasmid pXL2563.
• the strain DHl Maniatis et al., 1989 containing this plasmid is cultured in a 7-litre fermenter.
• a clear lysate is prepared from 200 grams of cells: the cell pellet is taken up in 2 litres of 25 mM Tris, pH 6.8, 50 mM glucose, 10 mM EDTA, to which 2 litres of 0.2 M NaOH, 1 % SDS, are added. The lysate is neutralized by adding one litre of 3M potassium acetate. After diafiltration, 4 ml of this lysate are applied to a 5 ml HiTrap-NHS column coupled to the oligonucleotide of sequence 5'-GAGGCTTCTTCTTCTTCTTCTTCTT ⁇ ' (SEQ ID NO: 1), according to the method described in Example 3. Washing and elution are carried out as described in the above Example.
• This example describes the use of an oligonucleotide bearing methylated cytosines.
• the sequence of the oligonucleotide used is as follows:
• This oligonucleotide possesses an NH 2 group at the 5' end.
• Mc C 5-methylcytosine. This oligonucleotide enables plasmid pXL2563 to be purified under the conditions of Example 1 with a binding buffer of pH 5 (the risk of degradation of the plasmid is thereby decreased).
• Example 8 the oligonucleotide used is modified at the 5'-terminal end with an amine group linked to the phosphate through an arm containing 6 carbon atoms: NH 2 -(CH 2 ) 6 .
• the amine group is linked to the phosphate of the 5'-terminal end through an arm containing 12 carbon atoms: NH 2 -(CH 2 )i 2 .
• Coupling of the oligonucleotide and passage through the column are carried out as described in Example 3 with a buffer F: 2 M NaCl, 0.2 M acetate, pH 4.5.
• This oligonucleotide makes it possible to have better purification yields: a 53 % yield is obtained, whereas, with the oligonucleotide containing 6 carbon atoms, this yield is of the order of 45 % under the same conditions.
• Example 9 Following the cloning strategy described in Example 3, another two plasmids carrying homopurine-homopyrimidine sequences are constructed: the plasmid pXL2725 which contains the sequence (GGA)i 6 , (SEQ ID NO: 20) and the plasmid pXL2726 which contains the sequence (GA) 25 (SEQ ID NO: 21).
• Plasmids pXL2725 and pXL2726 are constructed according to the cloning strategy described in Example 3, using the following oligonucleotide pairs: 5986: 5'-GATCC(GA) 25 GGG ⁇ ' (SEQ ID NO: 22) 5987: 5'-AATTCCC(TC) 25 G-S 1 (SEQ ID NO: 23) 5981 : 5'-GATCC(GGA) l7 GG-3' (SEQ ID NO: 24) 5982: 5'-AATT(CCT) 17 CCG ⁇ 1 (SEQ ID NO: 25)
• the oligonucleotide pair 5986 and 5987 is used to construct plasmid pXL2726 by cloning the oligonucleotides at the BamHI and EcoRI sites of pBKS+ (Stratagene Cloning System, La Jolla CA), while the oligonucleotides 59
• plasmid pXL2725 possesses a modification relative to the expected sequence: instead of the sequence GGA repeated 17 times, there is GGAGA(GGA) )5 (SEQ ID NO: 26).
• the oligonucleotides forming triple helices with these homopurine sequences are coupled to HiTrap columns according to the technique described in Example 1.1.
• the oligonucleotide of sequence 5'-AATGCCTCCTCCTCCTCCTCCTCCT-3 1 (SEQ ID NO: 27) is used for the purification of plasmid pXL2725
• Buffer F 2 M NaCl, 0.2 M acetate, pH 4.5.
• Buffer E 1 M Tris-HCl, pH 9, 0.5 mM EDTA.
• the yields obtained are 23 % and 31 % for pXL2725 and pXL2726, respectively.
• This example illustrates the influence of the length of the specific sequence present in the plasmid on the purification yields.
• the reporter gene used in these experiments to demonstrate the activity of the compositions of the invention is the gene coding for luciferase (Luc).
• the plasmid pXL2621 contains a cassette containing the 661-bp cytomegalovirus (CMV) promoter cloned upstream of the gene coding for luciferase, at the MIuI and HindIII sites, into the vector pGL basic Vector (Promega Corp., Madison, WI). This plasmid is constructed using standard techniques of molecular biology.
• CMV cytomegalovirus
• the plasmids pXL2727-l and pXL2727-2 are constructed in the following manner:
• plasmid pXL2621 Two micrograms of plasmid pXL2621 were linearized with BamHI; the enzyme was inactivated by treatment for 10 min at 65°C; at the same time, the oligonucleotides 6006 and 6008 are hybridized as described for the construction of plasmid pXL2563.
• 6006 5'-GATCT(GAA) 17 CTGCAGATCT ⁇ 1 (SEQ ID NO: 29)
• 6008 5'-GATCAGATCTGCAG(TTC), 7 A-3' (SEQ ID NO: 30).
• This hybridization mixture is cloned at the BamHI ends of plasmid pXL2621 and, after transformation into DH5 ⁇ , recombinant clones are identified by Pstl enzymatic restriction analysis, since the oligonucleotides introduce a Pstl site. Two clones are selected, and the nucleotide sequence of the cloned fragment is verified using the primer (6282, 5'-ACAGTCATAAGTGCGGCGACG-S' (SEQ ID NO: 31)) as a sequencing reaction primer (Viera J. and J. Messing, 1982).
• the pUC plasmid s an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. (Gene 19:259-268).
• the first clone (pXL2727-l) contains the sequence GAA repeated 10 times.
• the second (pXL2727-2) contains the sequence 5'-GAAGAAGAG(GAA) 7 GGAAGAGAA-3' (SEQ ID NO: 32).
• the plasmid pXL2727-l carries 14 repeats of the sequence GAA.
• the oligonucleotide described above which contains only 7 repeats of the corresponding hybridization sequence CTT, can hence hybridize with the plasmid at 8 different positions.
• Plasmid pXL2727-2 in contrast, possesses a hybridizing sequence (GAA) 7 (SEQ ID NO: 36) of the same length as that of the oligonucleotide bound to the column. This oligonucleotide can hence hybridize at only one position on pXL2727-2.
• the experiment is identical to the one described in Example 4, with the following buffers:
• Buffer F 2 M NaCl, 0.2 M acetate, pH 4.5.
• Buffer E I M Tris-HCl, pH 9, 0.5 mM EDTA.
• the purification yield is 29 % with plasmid pXL2727-l and 19 % with pXL2727-2.
• the cells used are NIH 3T3 cells, inoculated on the day before the experiment into 24-well culture plates on the basis of 50,000 cells/well.
• the plasmid is diluted in 150 mM NaCl and mixed with the lipofectant RPRl 15335.
• a lipofectant positive charges/DNA negative charges ratio equal to 6 is used.
• the mixture is vortexed, left for ten minutes at room temperature, diluted in medium without foetal calf serum and then added to the cells in the proportion of 1 ⁇ g of DNA per culture well.
• the following example demonstrates the purification of pCOR-derived plasmids using triple-helix affinity chromatography. This technology has been shown to remove nucleic acid contaminants (particularly host genomic DNA and RNA) down to levels that have not been achieved with conventional chromatography methods.
• a triplex affinity gel is synthesized with Sephacryl S-1000 SF (Amersham-Pharmacia Biotech) as the chromatography matrix.
• Sephacryl S-1000 is first activated with sodium m-periodate (3 mM, room temperature, 1 h) in 0.2 M sodium acetate (pH 4.7). Then the oligonucleotide is coupled through its 5'-NH 2 terminal moiety to aldehyde groups of the activated matrix by reductive amination in the presence of ascorbic acid (5 mM) as described previously for the coupling of proteins (Hornsey et al., J. Immunol. Methods, 1986, 93, 83-88).
• the homopyrimidine oligonucleotide used for these experiments had a sequence which is complementary to a short 14-mer homopurine sequence (5'- ⁇ AGAAAAAAAAGAA-3') (SEQ ID NO: 10) present in the origin of replication (ori ⁇ ) of the pCOR plasmid (Soubrier et al., Gene Therapy, 1999, 6, 1482-1488).
• the sequence of the homopyrimidine oligonucleotide is 5'-TTCTTTTTTTTCTT-S' (SEQ ID NO: 11).
• plasmids are chromatographed: pXL3296 (pCOR with no transgene, 2.0 kpb), pXL3179 (pCOR-FGF, 2.4 kpb), pXL3579 (pCOR- VEGFB, 2.5 kbp), pXL3678 (pCOR-AFP, 3.7 kbp), pXL3227 (pCOR-lacZ 5.4 kbp) and pXL3397 (pCOR-Bdeleted FVIII, 6.6 kbp). All these plasmids are purified by two anion-exchange chromatography steps from clear lysates obtained as described in example 4.
• Plasmid pBKS ⁇ (pBluescript II KS + from Stratagene), a CoIEl -derived plasmid, purified by ultracentrifugation in CsCl is also studied. All plasmids used are in their supercoiled (> 95 %) topological state or form.
• Plasmid recoveries in the fraction collected are 207 ⁇ g for pXL3296, 196 ⁇ g for pXL3179, 192 ⁇ g for pXL3579, 139 ⁇ g for pXL3678, 97 ⁇ g for pXL 3227, and 79 ⁇ g for pXL 3397.
• oligonucleotide 5'-TTCTTTTTTTTCTT-S' (SEQ ID NO: 1 1) makes stable triplex structures with the complementary 14-mer sequence 5'- AAG AA A AAAAAG AA-3' (SEQ ID NO: 10) present in pCOR (ori ⁇ ), but not with the closely related sequence 5'-AGAAAAAAAGGA-3' (SEQ ID NO: 8) present in pBKS.
• T*GC non-canonical triad
• the level of contamination by host genomic DNA was reduced from 2.6 % down to 0.07 % for a preparation of pXL3296.
• the level of contamination by host DNA is reduced from 0.5 % down to 0.008 % for a preparation of pXL3179 when the sample is chromatographed through the same affinity column.
• the following example demonstrates the purification of ColEl-derived plasmids using triple-helix affinity chromatography. This technology has been shown to remove nucleic acid contaminants (particularly host genomic DNA and RNA) down to levels that have not been achieved with conventional chromatography methods.
• a triplex affinity gel is synthesized by coupling of an oligonucleotide having the sequence 5'-TCTTTTTTTCCT-S' (SEQ ID NO: 9) onto periodate-oxidized Sephacryl S-1000 SF as described in the above Example.
• Plasmids pXL3296 (pCOR with no transgene) and pBKS, a CoIEl -derived plasmid, are chromatographed on a 1-ml column containing oligonucleotide 5'-TCTTTTTTTCCT-S 1 (SEQ ID NO: 9) in conditions described in Example 9. Plasmid recoveries in the fraction collected are 175 ⁇ g for pBKS and ⁇ 1 ⁇ g for pXL3296.
• oligonucleotide 5'-TCTTTTTTTCCT-S' makes stable triplex structures with the complementary 12-mer sequence (5'-AGAAAAAAAGGA-3') (SEQ ID NO: 8) present in pBKS, but not with the very closely related 12-mer sequence (5 '-AG A AA AAAAAG A-3') (SEQ ID NO: 34) present in pCOR.
• a seed culture is produced in an unbaffled Erlenmeyer flask by the following method.
• the working cell bank is inoculated into an Erlenmeyer flask containing M9modG5 medium, at a seed rate of 0.2%v/v.
• the strain is cultivated at 220 rpm in a rotary shaker at 37° ⁇ 1°C for about 18 ⁇ 2 hours until glucose exhaustion. This results in a 200 ml seed culture.
• the optical density of the culture is expected to be A 60 O around 2-3.
• a pre-culture in a first fermentor is then created.
• the seed culture is aseptically transferred to a pre-fermentor containing M9modG5 medium to ensure a seed rate of 0.2% (v/v) and cultivated under aeration and stirring.
• the p ⁇ 2 is maintained above 40% of saturation.
• the culture is harvested when the glucose is consumed after 16 hours. This results in about 30 liters of pre-culture.
• the optical density of the culture is expected to be A 6 oo around 2-3.
• a main culture is then created in a second fermentor.
• 30 liters of preculture are aseptically transferred to a fermentor filled with 270 liters of sterilized FmodG2 medium to ensure a seed rate of about 10% (v/v).
• the culture is started on a batch mode to build some biomass.
• Glucose feeding is started once the initial sugar is consumed after about 4 hours.
• Aeration, stirring, p ⁇ 2 (40%), pH (6.9 ⁇ 0.1), temperature (37 ⁇ 1°C) and glucose feeding are controlled in order to maintain a specific growth rate close to 0.09h ' ⁇
• the culture is ended after about 35 hours of feeding. This results in about 400 liters of culture.
• the optical density of the culture is expected to be A 60O of about 100.
• a first separation step is performed, which is called cell harvest.
• the biomass is harvested with a disk stack centrifuge.
• the broth is concentrated 3- to 4-fold to eliminate the spent culture medium and continuously resuspended in 400 liters of sterile Sl buffer. This results in about 500 liters of pre ⁇ conditioned biomass.
• DCW 25 ⁇ 5 g/L.
• a second separation step is performed, which is called a concentration step.
• the cells are processed again with the separator to yield concentrated slurry. This results in about 60-80 liters of washed and concentrated slurry.
• a freezing step is then performed.
• the slurry is aseptically dispatched into 20-L FlexboyTM bags (filled to 50% of their capacity) and subsequently frozen at -20° + 5°C before further downstream processing. This results in a frozen biomass.
• pDNA 300 ⁇ 60 mg/L ; supercoiled form > 95 % .
• a cell thawing step is then performed.
• the cell lysis step is comprised of pumping the diluted cell suspension via an in-line mixer with a solution of 0.2 N NaOH-35 mM SDS (solution S2), followed by a continuous contact step in a coiled tubing.
• the continuous contact step is to ensure complete cell lysis and denaturation of genomic DNA and proteins.
• the solution of lysed cells is mixed in-line with solution 3 (S3) of chilled 3 M potassium acetate-2 N acetic acid, before collection in a chilled agitated vessel.
• S3 solution 3
• the addition of solution S3 results in the precipitation of a genomic DNA, RNA, proteins and KDS.
• a lysate filtration is performed next.
• the neutralized lysate is then incubated at 5 ⁇ 3 0 C for 2 to 24 h without agitation and filtered through a 3.5 mm grid filter to remove the bulk of precipitated material (floe phase) followed by a depth filtration as polishing filtration step. This results in a clarified lysate, with a concentration of supercoiled plasmid of more than 90%.
• the clear lysate solution is diluted with purified water to a target conductivity value of 50 mS/cm, filtered through a double-layer filter (3 ⁇ m- 0.8 ⁇ m) and loaded onto an anion-exchange chromatography column.
• a 300-mm column packed with 11.0 L Fractogel® TMAE HiCap (M) resin (Merck; #1.10316.5000) is used.
• the clear lysate is loaded onto the column and elution is performed using a step gradient of NaCl.
• the bulk of contaminants bound to the column are eluted with a NaCl solution at about 61 mS/cm, and DNA plasmid is eluted with a NaCl solution at about 72 mS/cm. This results in an ion exchange chromatography eluate having a high concentration of plasmid DNA.
• the eluate from the anion exchange chromatography column is diluted with about 0.5 volumes of a solution of 500 mM sodium acetate (pH 4.2) containing 4.8 M NaCl and pumped through a triplex affinity chromatography column equilibrated with 50 mM sodium acetate (pH 4.5) containing 2 M NaCl.
• the column is 300 mm in diameter and contains 10.0 L of THAC SephacrylTM S-1000 gel (Amersham Biosciences; Piscataway, NJ).
• the column is washed with a solution of 50 mM sodium acetate (pH 4.5) containing 1 M NaCl and NVlFGF is eluted with 100 mM Tris (pH 9.0) containing 0.5 mM EDTA. This results in a triplex affinity chromatography eluate having a high plasmid concentration.
• a hydrophobic interaction chromatography step follows.
• the eluate of the affinity chromatography column is diluted with 3.6 volumes of a solution of 3.8 M ammonium sulfate in Tris (pH 8.0).
• the filtrate is loaded at 60 cm/h onto a hydrophobic interaction column (diameter 300 mm) packed with 9.0 L of Toyopearl® Butyl-650S resin (TosoH corp., Grove City, OH).
• the column is washed with a solution of ammonium sulfate at about 240 mS/cm and NVlFGF is eluted with ammonium sulfate at 220 mS/cm. This results in an HIC eluate free of relaxed forms.
• a further diafiltration step is performed.
• Standard, commercially available diafiltration materials are suitable for use in this process, according to standard techniques known in the art.
• a preferred diafiltration method is diafiltration using an ultrafiltration membrane having a molecular weight cutoff in the range of 30,000 to 500,000, depending on the plasmid size. This step of diafiltration allows for buffer exchange and concentration is then performed.
• the eluate of step 12 is concentrated 3- to 4-fold by tangential flow filtration (membrane cut-off, 30 kDa) to a target concentration of about 2.5 to 3.0 mg/mL and the concentrate is buffer exchanged by diafiltration at constant volume with 10 volumes of saline and adjusted to the target plasmid concentration with saline.
• NVlFGF concentration is calculated from the absorbance at 260 nm of samples of concentrate.
• NVlFGF solution is filtered through a 0.2 ⁇ m capsule filter and stored in containers in a cold room at 2-8 0 C until further processing.
• This yields a purified concentrate with a plasmid DNA concentration of supercoiled plasmid is around 70%, 75%, 80%, 85%, 90%, 95%, and preferably 99%.
• the overall plasmid recovery with this process is at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, and 80%, with an average recovery of 60 %.
• Combination of these steps provide a clear synergy in terms of efficacy of separation of plasmid DNA from other biological materials and contaminants, such as protein and endotoxin, RNA and genomic DNA, as well as open circular plasmid.
• the synergistic steps combination i.e., AEC/THAC/HIC according to the present invention enables not only to obtain highly purified pharmaceutically grade plasmid DNA, but also compositions of highly pure and fully supercoiled, of more than 80%, 85%, 90%, 95% and more than 99% plasmid DNA.
• the method of the above Example which comprises an ion-exchange chromatography step, a triple helix affinity chromatography step, and a hydrophobic chromatography step for the preparation of highly purified plasmid DNA preparation is compared to previously known methods.
• the method according to the present invention surprisingly results in pDNA preparations having much lower amounts of genomic DNA, RNA, protein, and endotoxin, in the range of the sub- ppm.
• the process of the present invention shows a product quality obtained at up to 1Og.
• the diafiltration step as described in Example 14 is performed according the following conditions: buffer for step a and for step b were used to determine the best conditions for: iii) a first diafiltration (step a) against 12.5 to 13.0 volumes of 50 mM Tris/HCl, 150 mM NaCl, pH 7.4 (named buffer I), and iv) Perform a second diafiltration of the retentate from step a) above (step b) against 3.0 to 3.5 volumes of saline excipient (150 mM NaCl).
• This alternative diafiltration step according to the present invention efficiently and extensively removes ammonium sulfate and EDTA extensively. Also, subsequent to this diafiltration steps, appropriate target NaCl concentration around 150 mM and final Tris concentration between 400 ⁇ M and 1 mM are obtained. Examples of plasmid DNA formulations compositions are provided in the Table 6 below, and
• LS06 is manufactured according to Examples 13 and 17 with the diafiltration process step described in Example 17.
• the eluate is first diafiltered at around 2 mg API /mL against about 13 volumes of buffer I and the resulting retentate was diafiltered against about 3 volumes of saline excipient.
• the final retentate was then filtered through a 0.2 ⁇ m filter and adjusted to 1 mg/mL.
• the final API (pH 7.24) was stored in a glass bottle at +5°C until DP manufacturing.
• LS04, LS04, LS06, LS07, and LT05 were manufactured according to Example 13 with the diafiltration process step described in Example 17.
• the eluate was first diafiltered at around 2 mg API /ml against about 13 volumes of buffer I and the resulting retentate was diafiltered against about 3 volumes of saline excipient.
• the final retentate was then filtered through a 0.2 ⁇ m filter and adjusted to 1 mg/ml for storage in 8 ml vials. Plasmid DNA having a NaCl concentration around 150 itiM and final Tris concentration between ImM and 2mM are obtained.
• the depurination and nicking rates at +25°C were about 1.0 % per month and appeared linearly dependent on time over 140 days.
• the depurination rate of LS04 was significantly higher (2.7 % per month) because of the significantly lower pH of this API batch (> 0.4 unit at T 0 ).
• the nicking rate of LS04 was slightly lower than its depurination rate (2.4 % per month).

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Genetics & Genomics (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• General Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Biotechnology (AREA)
• Biomedical Technology (AREA)
• General Health & Medical Sciences (AREA)
• Plant Pathology (AREA)
• Microbiology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• General Chemical & Material Sciences (AREA)
• Cardiology (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Heart & Thoracic Surgery (AREA)
• Veterinary Medicine (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Crystallography & Structural Chemistry (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Publications (1)

Family

ID=56290732

Family Applications (1)

Country Status (14)

Families Citing this family (13)

Family Cites Families (3)

• 2005
  • 2005-09-19 KR KR1020077008629A patent/KR20070058621A/ko not_active Application Discontinuation
  • 2005-09-19 CA CA002579340A patent/CA2579340A1/en not_active Abandoned
  • 2005-09-19 CN CNA2005800351740A patent/CN101040041A/zh active Pending
  • 2005-09-19 WO PCT/EP2005/010881 patent/WO2006029908A1/en active Application Filing
  • 2005-09-19 AU AU2005284244A patent/AU2005284244A1/en not_active Abandoned
  • 2005-09-19 NZ NZ553914A patent/NZ553914A/en not_active IP Right Cessation
  • 2005-09-19 JP JP2007531725A patent/JP2008512997A/ja active Pending
  • 2005-09-19 EP EP05795460A patent/EP1791945A1/en not_active Ceased
  • 2005-09-19 EA EA200700656A patent/EA011554B1/ru not_active IP Right Cessation
  • 2005-09-19 BR BRPI0515553-3A patent/BRPI0515553A/pt not_active IP Right Cessation
  • 2005-09-19 MX MX2007003214A patent/MX2007003214A/es unknown
• 2007
  • 2007-03-06 IL IL181753A patent/IL181753A0/en unknown
  • 2007-03-08 TN TNP2007000087A patent/TNSN07087A1/en unknown
  • 2007-04-17 NO NO20071946A patent/NO20071946L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events